

- P001-P039 AAV vector development
- P040-P087 Viral vectors manufacturing
- P090-P160 Cancer
- P161-P189 Next generation engineered T&NK cells
- P195-P236 Blood diseases
- P240-P290 CNS gene therapy
- P295-P320 Eye and ear gene therapy
- P325-P326 First in man
- P330-P353 Immune responses to gene therapy
- P354-P402 iPSC & organoids, research and therapy developments
- P405-P412 Latest news from cardiovascular and pulmonary gene therapy
- P415-P436 Liver gene and cell therapy
- P440-P474 Metabolic diseases
- P478-P526 Skeletal, muscle & bone gene and cell therapy
- P530-P544 Skin gene and cell therapy
- P549-P595 New approaches in gene editing
- P600-P650 New delivery systems
- P655-P669 Regulatory session
- P670-P706 Other

Catering and seating

AAV vector development

P001

Qiang Wang *University of Pennsylvania, Philadelphia, PA*

Development of AAV3B variants with better liver transduction in nonhuman primates by directed evolution

P003

Marti Cabanes-Creus *Children's Medical Research Institute*

Restoring the intrinsic AAV2 human hepatotropism attenuated by tissue culture adaptation

P005

Cody Jackson *The Scripps Research Institute*

Development of a novel adeno-associated virus capsid for markedly enhanced muscle transduction

P007

Brian Kevany *Abeona Therapeutics*

Development of a novel AAV capsid with improved PNS tropism for treating Pompe disease by intravenous administration

P009

Brian Kevany *Abeona Therapeutics*

Novel AAV capsids for delivery to the retina by intravitreal administration

P011

Subha Karumuthil Melethil *ReGenX Biosciences*

Characterization of a novel AAV capsid with enhanced brain transduction following systemic delivery

P013

James Warren *Ultragenyx Gene Therapy*

Rapid CMC development and pre-commercial considerations for rAAV gene therapy products for rare diseases

P015

Erwan Sallard *The University of Sydney*

AAV p40 promoter expression in the absence of Rep proteins

P017

Silke Wissing *Cevec Pharmaceuticals GmbH, Cologne*

Scalable AAV production using stable helper virus-free AAV producer cell lines based on CEVEC's CAP-GT cells

P019

Adrian Westhaus *Children's Medical Research Institute*

Finding the perfect match: Directed AAV vector development guided by Targeted High Expression.

P021

Caroline Odenwald *PROGEN Biotechnik GmbH*

Cryo and negative staining EM – a comparison study with AAV capsids

P023

Veronique Blouin *Université de Nantes*
Advantages of homologous recombination-over transposition-based systems to generate recombinant baculovirus for AAV vector production

P025

Marti Cabanes-Creus *Children's Medical Research Institute*
AAV development program: towards next generation of livertropic AAV variants

P027

Linas Padegimas *Abeona Therapeutics*
Development of an improved novel AAV capsids for intramuscular delivery

P029

Joris van Arensbergen *Gen-X B.V.*
SuRE: an unbiased, genome-wide assay to identify regulatory elements for custom-made gene expression

P031

Peter Pechan *Solid Biosciences*
Evaluation of rAAV vectors engineered for muscle gene delivery

P033

Veronique Blouin *Université de Nantes*
Improving the high-throughput sequencing of adeno associated viral vector genome using an optimized PCR-free protocol

P035

Susan D'Costa *Thermo Fisher Scientific*
Scalable chromatographic enrichment of full AAV capsids

P037

Yohann Dickx *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Molecular design optimization towards the development of a high scale rAAV8 production process using BEVS

P039

Elena Iurlova *Biotechnology company BIOCAD, Saint-Petersburg*
Development of new AAV extraction protocol for titration AAV using quantitative PCR and ELISA

Viral vectors manufacturing

P041

Laura Garcia Perez *Leiden University Medical Center*
A new gene therapy method to assess transduction efficiency at the single-cell level.

P043

Cristina Nogueira *Oxford BioMedica*
Development of secreted nucleases to eliminate residual DNA during viral vector manufacture

P045

Cristina Peixoto *iBET*
Accelerating lentivirus manufacturing to the clinical

Poster session I: Wednesday 23 October

P047

Hanna Leinonen *Kuopio Center for Gene and Cell Therapy Oy*
Comparison of lentiviral vector production in two fixed-bed bioreactors

P049

Josh Grieger *Asklepios Biopharmaceutial, Inc*
Development, optimization and scalability of the Pro10 rAAV manufacturing process

P051

Giuliana Vallanti *MolMed S.p.A.*
Lentiviral/Retroviral Vector large scale manufacturing

P053

Adrien Soula *Cell Therapy Catapult*
Development of a Scalable platform for AAV manufacturing

P055

Vincenzo Di Cerbo *Cell Therapy Catapult*
Single cell analysis of lentiviral integration to support ex-vivo gene modified cell therapy development

P057

Corinne Branciaroli *Oxford Genetics Ltd*
Generation of cGMP-compliant stable packaging cell lines for inducible recombinant adeno-associated viral (rAAV) vector production

P059

Fulya Erendor *Gene and Cell Therapy Center*
LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes

P061

Keerang Park *Chungbuk Health & Science University*
The establishment of highly sensitive real time-PCR-based detection methods of GMP-manufactured biological products for 14 human viral pathogens

P063

Emanuele Bourges *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
PTG1plus, a novel yransfection agent for a better AAV productivity in large-scale bioreactors

P065

Ana Sofia Moreira *iBET*
3D printing in bioprocessing: Chromatographic purification of viral vectors

P067

Nicholas Clarkson *Oxford BioMedica*
High-throughput data capture and analysis of scale down lenti viral vector production systems during process development

P069

Mélissa Desrosiers *Sorbonne Université*
Retrospective analysis of factors influencing AAV titers based on 1300 preparations.

P071

Ana Sofia Moreira *iBET*
Integrating design of experiments to improve Lentiviral purification

P073

Tom Payne *Oxford Genetics Ltd*
Development of automated platforms for high-throughput screening of clonal viral packaging and producer cell lines

P075

Andrew Laskowski *Pall Life Sciences*
Adherent HEK293t cells cultured in the Pall iCELLis® bioreactor with OptiPEAK HEK293t blood-free chemically defined media exhibit robust and rapid population doubling times

P077

Keerang Park *Chungbuk Health & Science University*
An *in vivo* method for detecting bovine herpes virus 1 as a possible adventitious contaminant utilising real-time PCR analysis

P079

Mégane Denu *Polyplus Transfection*
High quality transfection reagents for therapeutic virus production

P081

Jessica De Rooij *Thermo Fisher Scientific*
Accelerating advancement in gene therapy by improving downstream purification of viral vectors

P083

Maurizio Cattaneo *Artemis Biosystems*
Continuous perfusion for an order of magnitude increase in lentiviral vector production

P085

Jessica de Rooij *Thermo Fisher Scientific*
Addressing viral vector manufacturing challenges – innovative solutions in the AAV production workflow

P087

Luyuan Jin *Beijing Stomatological Hospital, Capital Medical University*
The Coding RNA and LncRNA expression profile analysis of stem cells from the apical papilla after depletion of SIRT7

Cancer

P091

Daniela Paasch *Hannover Medical School*
Generation of Chimeric Antigen Receptor (CAR) macrophages from Human Haematopoietic Stem/Progenitor Cells (HSPCs)

P093

Eric Ehrke-Schulz *Witten/Herdecke University, Witten*
Single adenoviral vectors armed with HPV oncogene specific CRISPR/Cas9 as efficient tumor gene therapy tools for HPV related cancers

P095

Marta Martinez-Lage *Centro Nacional de Investigaciones Oncológicas*
CRISPR-mediated targeting of fusion oncogenes for cancer-directed therapy

Poster session I: Wednesday 23 October

P097

Leysan Minigulova *Kazan Federal University*
Charge balance rule in the assembly of integral membrane proteins in tumor cells

P099

Julia Davydova *University of Minnesota*
Clinical translation of a novel NIS-expressing oncolytic adenovirus for pancreatic cancer therapy and imaging

P101

Biagio De Angelis *Ospedale pediatrico Bambino Gesù, Rome*
A new promising CAR.CD30 T cell therapy associated with long persistence and high activity for treatment of CD30 positive lymphomas

P103

Natasha Oppermans *University of Manchester*
Analysis of tumour reactivity and Vβ repertoire of melanoma TIL patients

P105

Daria Chulpanova *Kazan Federal University*
Analysis of the interaction of mesenchymal stem cells overexpressing interferon alpha-17 and human neuroblastoma in co-culture *in vitro*

P107

Jaitip Tipanee *Vrije Universiteit Brussel*
Validation of tumor suppressor microrna In liver tumorigenesis using hepatocyte-specific hyperactive piggybac transposons

P109

Tomoko Ito *Japan Anti-tuberculosis Association, Shin-Yamanote Hospital*
Development of "Artificial neoepitope"-presenting exosomes for novel cancer immunotherapy

P111

Erica Carnevale *San Raffaele Scientific Institute, Milan*
Generation of a library of WT1-specific T Cell receptors (TCR) for TCR gene edited T Cell therapy of acute leukemia

P113

Rafael Moreno *IDIBELL-ICO*
Enhanced antitumor efficacy of armed oncolytic adenovirus-loaded menstrual blood-derived mesenchymal stem cells in combination with peripheral blood mononuclear cells

P115

Javier Garcia Castro *Universidad Alfonso X el sabio*
Cellular viroimmunotherapy as a treatment to spontaneous canine supratentorial gliomas

P117

Maria del Pilar Martin Duque *Instituto Aragonés de Ciencias de la Salud*
Use of Placental MSCs and their exosomes as theragnostic agents for cancer treatment and diagnostic

P119

John Rossi *Kite, a Gilead Company*
Pretreatment immunoscore and an inflamed tumour microenvironment are associated with efficacy in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel in ZUMA-1

P121

Samanta Romina Zanetti *Josep Carreras Leukemia Research Institute, Barcelona*
CD19 and CD22-directed biespecific CAR for B-cell Acute Lymphoblastic Leukemia

P123

Yoshiyuki Koyama *Japan Anti-tuberculosis Association Shin-Yamanote Hospital*
Antitumour immune activation by "artificial neoantigen"-presenting exosomes derived from the genetically modified cells

P125

Claudia Manuela Arnone *Bambino Gesù Children's Hospital, Rome*
Novel approach for treatment of pediatric high-grade gliomas through the combination of oncolytic adenoviruses and gene therapy encoding a BiTE directed to the EphA2 tumor antigen.

P127

Chin Yang Chang *Osaka University*
HVJ-E in combination with CXCL2 suppressed murine melanoma through neutrophil-mediated anti-tumor effect

P129

Franziska Köhler *Institute for Anatomy, University Medicine Leipzig*
Adeno-associated virus vectors (AAV) transduce human primary neurospheres and slice cultures of glioblastoma multiforme

P131

Alvaro Morales-Molina *Instituto de Salud Carlos III*
AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytical adenoviruses

P133

Shuji Kubo *Hyogo College of Medicine*
Human mesenchymal stem cells as tumor-homing cellular carriers of retroviral replicating vectors for cancer gene therapy

P135

Lara Herrera del Val *Centro Vasco de Transfusión y Tejidos Humanos*
Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against cd19 positive leukemic cells

P137

Raul Torres *Centro Nacional de Investigaciones Oncológicas*
CRISPR-mediated rearrangement generation of t(4;11) in human prenatal and perinatal haematopoietic stem/progenitor cells

P139

Ilnur Ishmukhametov *Kazan Federal University*
Intravital visualization of magnetic nanoparticles in eukaryotic cells using dark-field microscopy

Poster session I: Wednesday 23 October

P141

Eleni Kalafati *University of Athens School of Medicine*
The novel oncolytic lentiviral vector expressing IFNβ and pseudotyped with the measles virus HF glycoproteins displays therapeutic efficacy as a gene therapy-based approach for multiple myeloma

P143

Mikhail Durymanov *Moscow Institute of Physics and Technology*
Influence of physiologically active agents on polyplex-mediated systemic gene delivery to melanoma tumours

P145

Dirk Strunk *Paracelsus Medical University Salzburg*
AML-derived extracellular vesicles transmit immunomodulatory potential

P147

Kristina Havrysh *Kazan Federal University*
The combined action of cisplatin and physcion increases the ROS level in the lung and pancreas cancer cells

P149

Bryan Strauss *Instituto do Cancer do Estado de Sao Paulo*
Induction of cell death in human melanoma cell lines by the combination of p14ARF plus interferon-β gene transfer

P151

María Sancho *Universidad de Zaragoza*
Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis

P153

Kristina Kitaeva *Kazan Federal University*
Production of mouse mesenchymal stem cell lines with Luciferase and Katushka2s reporter gene expression for bioluminescence imaging

P155

Kyuri Lee *Ewha Womans University*
Development of lipid nanoparticles for the mRNA-mediated cancer immunotherapy

P157

Kristina Havrysh *Kazan Federal University*
SLC34A2 as a potential prognostic marker of triple-negative breast cancer patients' survival

P159

Kristina Kitaeva *Kazan Federal University*
Analysis of Rac1, Bcl2, Cav1α, and Cav1β gene expression of neuroblastoma cells, mesenchymal stem cells and human peripheral blood mononuclear cells after co-cultivation

Next generation engineered T&NK cells

P161

Gregory Cost *Casebia Therapeutics*
Expansion of genetically engineered regulatory T cells *in vitro* and *in vivo* via signaling through a synthetic, small-molecule-controlled IL-2 receptor

P163

Concetta Quintarelli *Ospedale pediatrico Bambino Gesù - Rome*
Allogenic CAR.CD19 natural killer cells: a new immuno-gene-therapy "off-the-shelf" in the treatment of acute lymphoblastic leukaemia.

P165

Daniel Abate-Daga *H. Lee Moffitt Cancer Center and Research Institute*
γδ CAR-T cell therapy for bone metastatic castrate resistant prostate cancer

P167

Julia Hambach *University Medical Center Hamburg-Eppendorf*
Engineering NK cells to express nanobody-based Chimeric Antigen Receptors (CARs)

P169

Matteo Doglio *San Raffaele Scientific Institute, Milan*
CAR-Tregs for the treatment of Systemic Lupus Erythematous

P171

Peer Heine *MaxCyte, Inc*
Gene editing: Paving the way for accelerated clinical development of adoptive cell immunotherapies

P175

Roberta Sommaggio *Veneto Institute of Oncology IOV – IRCCS, Padova*
Antigen-specific targeting of triple negative breast cancer using Cytokine-Induced Killer cells redirected with monoclonal antibodies

P177

María Tristán-Manzano *GENyO*
LVs development for a fine-tuned regulation of CARs in T cells

P179

Lorena Pérez Amill *IDIBAPS*
Development of an efficient transduction protocol for CAR-19 in cord blood derived-NK cells

P181

Roland Leathers *Thermo Fisher Scientific*
PureQuant real-time PCR-based assay for quantitative determination of immune cell identity and purity

P183

Arthur Bister *Heinrich Heine University Dusseldorf*
Combining ROR1, CD5 or CD19 targeted chimeric antigen receptors reduces off-tumour toxicity while maintaining lysis against double-positive mantle cell lymphoma cells

Poster session I: Wednesday 23 October

P185

Tatsuji Enoki *Takara Bio Inc.*
Development of robust T-cell expansion system and single-cell analysis of their expanded cells

P187

Abeer ALhubaysh *University College London*
Investigating Optimal Storage Conditions in the Manufacture of CAR-T cells

P189

Aude-marie Alem *JPT Peptide Technologies GmbH*
A new transduction enhancer accelerates CAR-T production

Blood diseases

P195

Penelope Georgia Papayanni *George Papanicolaou Hospital, Thessaloniki*
Dual functioning, novel chromatin insulators incorporated in lenti-viral vectors (LVs) for safer and more effective haematopoietic stem cell (HSC) gene therapy

P197

Eleni Papanikolaou *Miltenyi Biotec, Bergisch-Gladbach*
Automation in hemopoietic stem cell gene therapy: Results of a head-to-head comparison of a manual vs an automated procedure

P199

Francesco Manfredi *San Raffaele Scientific Institute, Milan*
Harnessing HLA-TCR interaction and the exhaustion signature for the isolation of tumor-specific T lymphocyte

P201

Alessio Cantore *SR Tiget, Milan*
Liver-directed gene therapy with lentiviral vectors achieve normal levels of clotting factor VIII and IX in non-human primates

P205

Maria Carmina Castiello *SR Tiget, Milan*
Non-genotoxic conditioning CD45-SAP promotes immunological reconstitution in a mouse model of Severe Combined Immunodeficiency caused by RAG1 defect

P207

Hai-jie Wang *Shanghai Medical School of Fudan University*
Transplantation of lymphatic endothelial progenitor cells and sustained release of VEGF-C promote cardiac lymphangiogenesis after myocardial infarction

P209

Winston Vetharoy *University College London*
Preclinical evaluation of the pCCLCHIM-p47 lentiviral vector for the gene therapy of p47phox deficient Chronic Granulomatous Disease

P211

Mégane Brusson *INSERM UMR 1163, Imagine Institute, Paris*
A novel lentiviral vector for gene therapy of β-hemoglobinopathies: Co-expression of a potent anti-sickling transgene and a microRNA downregulating BCL11A

P213

Verónica Palma Barqueros *Universidad de Murcia*
Towards the lentiviral-mediated gene therapy for Glanzmann thrombasthenia

P215

Bridget Yates *BioMarin Pharmaceutical*
Vector genome processing of AAV5-hFVIII-SQ in mouse and monkey livers

P217

Carlos Carrascoso-Rubio *CSIC/UAM, Madrid*
Preclinical studies of a gene therapy approach for the bone marrow failure in X-linked dyskeratosis congenita

P219

Antonella Bastone *Hannover Medical School*
Development of a new all-in-one *in vitro* safety assay for gene therapy

P221

Sami Jalil *University of Helsinki*
Increasing fetal hemoglobin by genetic editing of sickle cell disease patient haematopoietic stem cells

P223

Baolei Yuan *King Abdullah University of Science and Technology*
Complete knockout of the Wiskott-Aldrich syndrome gene impairs phagocytosis and chemotaxis and enhances proliferation in macrophages

P225

Mathieu Streefland *Kiadis Pharma, Amsterdam*
Development of a fully-closed and automated manufacturing process for ATIR101: Donor lymphocytes depleted of host alloreactive T-cells

P229

Flaminia Clelia Lorenzetti *Medical Genetics, University of Siena*
Patient-specific TP53 mutations CRISPR-Cpf1 editing in chronic lymphocytic leukemia by suicide gene delivery

P231

Maria Jose Sanchez *CABD, CSIC, UPO, Seville*
Fetal liver haemato/vascular progenitor cells as a cell-based therapeutic tool for neonatal haemophilia

P233

Roland Leathers *Thermo Fisher Scientific*
StemPro™ HSC expansion medium supports superior expansion of human haematopoietic stem-progenitor cells

Poster session I: Wednesday 23 October

Other

P235

Michaela Öller *Paracelsus Medical University Salzburg*
Human plasma and platelets from neonatal and adult blood express differential sets of regenerative proteins

CNS gene therapy

P241

Michaël Hocquemiller *Lysogene*
LYS-SAF302 gene therapy study in mucopolysaccharidosis type IIIA (mps IIIA) children

P243

Freja Ekman *University of California, Berkeley*
CRISPR-Cas9-mediated genome editing improves motor deficits and lifespan in a mouse model of Huntington's disease

P245

Yoshie Kurokawa *Jichi Medical University*
Gene therapy in a murine model of Niemann-Pick disease type C

P247

Lodewijk Toonen *uniQure biopharma B.V.*
A novel AAV-based miQURE gene therapy for SCA3

P249

Assumpcio Bosch *Univeristat Autònoma de Barcelona*
Broad and specific expression of Glial-Derived Neurotrophic Factor (GDNF) in muscles as gene therapy strategy for Amyotrophic Lateral Sclerosis

P251

Sara Marcó Costa *Center for Animal Biotechnology and Gene Therapy*
Safe and sustained elevation of sulfamidase after administration of AAV9-sulfamidase to the CSF of dogs: Seven year-follow up

P253

David Scott *Aspa Therapeutics*
A route of administration study of BBP-812, an AAV9-based gene therapy for the treatment of Canavan disease, in juvenile cynomolgus macaques

P255

Françoise Piguet *INSERM U1127, NeuroGenCell, Brain and spine Institute, Paris*
Restoring neuronal cholesterol efficiently rescues ALS mouse model

P257

Kamal Gadalla *University of Edinburgh*
Gene transfer rescues established phenotypes in a mouse model of Rett syndrome

P259

Annita Montepeloso *Harvard Medical School, Boston, MA*
Improving the ability of haematopoietic stem cells to generate a microglia-like progeny upon transplantation

P261

Matthew Meriggioli *AveXis, Inc.*
Adeno-associated virus serotype 9 (AAV9) antibodies in patients with spinal muscular atrophy (SMA) screened for treatment with onasemnogene abeparvovec

P263

Lucía Mora Jiménez *CIMA, Universidad de Navarra*
Delivery of the SCN1A into the brain using High-Capacity Adenoviral vectors for the treatment of Dravet Syndrome

P265

Marisa Cappella *Sorbonne Université, Inserm UMRS 974, Institut de Myologie*
AAV-mediated expression of antisense oligonucleotides for the treatment of C9orf72-ALS

P267

Michaël Hocquemiller *Lysogene*
PROVide: Video based Patient Reported Outcomes for Sanfilippo Syndrome (MPS IIIA): A new and innovative approach to record and measure disease post gene therapy.

P269

Kelly Glajch *Biogen*
AAV gene therapy for Parkinson's disease: *in vitro* and *in vivo* effects of AAV-GBA treatment in GBA mutant models

P273

Valentina Poletti *Harvard Medical School, Boston, MA*
Long term effect of prostaglandin E2 exposure on haematopoietic stem/progenitor cells

P275

Eva Hede Olsen *Aalborg University*
Gene therapy to the blood-brain barrier with resulting protein secretion as a strategy for treatment of NPC2 disease

P277

Joan Roig Soriano *Univeristat Autònoma de Barcelona*
AAV-mediated over-expression of secreted and transmembrane αKlotho isoforms reverse cognitive and molecular aging hallmarks in senescent mice

P279

Francesca Ornaghi *SR Tiget, Milan*
Optimized bicistronic lentiviral vectors to correct β-hexosaminidase deficiency in neural and haematopoietic stem/progenitor cells and progeny

P281

Beihui Liu *Oxford BioMedica*
Targeting neurodegeneration using lentiviral gene therapy

P283

Natalia Bal *Institute of Higher Nervous Activity and Neurophysiology of RAS, Moscow*
DNA cytosine methylation contributes to long-term memory maintenance in snails

Poster session I: Wednesday 23 October

P285

Ilnur Ishmukhametov *Kazan Federal University*
Pharmacological protection of the spinal cord in the first hours after injury

P289

Elvira Akhmetzyanova *Kazan Federal University*
Investigation of microglia cells behavior in spinal cord injury of varying severity

Eye and ear gene therapy

P295

Shubham Maurya *Indian Institute of Technology Kanpur India*
Ocular gene therapy with a synthetically engineered AAV enhances visual function in a pre-clinical model of Leber congenital amarousis

P297

Bernard Schneider
École Polytechnique Fédérale de Lausanne
Delivery of CRISPR/Cas9 using AAV-PHP.B in the inner ear leads to allele-specific inactivation of the mutated Tmc1 allele and protects auditory function in Beethoven mice

P299

William Beltran *University of Pennsylvania, Philadelphia, PA, USA*
Long-term efficacy of rhodopsin knockdown and replacement gene therapy in a canine model of autosomal dominant retinitis pigmentosa

P301

Rob Collin *Radboud University MC*
Splice modulation therapy for a variety of ABCA4 mutations underlying Stargardt disease

P303

Fabio Dell'Aquila *TIGEM*
Towards a clinical trial of gene therapy for Usher syndrome type IB retinitis pigmentosa

P307

Carrie Margulies *Editas Medicine*
Developing a CRISPR/Cas9 editing approach for the treatment of USH2A-related inherited retinal degeneration

P309

Gaelle Chauveau *Université d'evry*
Subretinal injection of rAAV2/8 vector induces dose-dependent retinal alteration and systemic anti-transgene T-cell response similarly in wild type and pathophysiological murine models

P311

Ning Chang *Jules-Gonin Eye Hospital, UNIL*
Towards the gene therapy for FAM161A associated retinitis pigmentosa in a murine model

P313

Therese Cronin *Inserm UMR 1089*
ABCA4 gene dysfunction in Stargardt retinal disease: Charcaterisation of two new rat transgenic models

P315

Martina Kropp *HUG*
Ex vivo efficacy study to evaluate neuroprotection in a retinal organotypic culture system: A gene therapeutic strategy to deliver growth factors to the retina to treat avascular age-related macular degeneration

P317

Nina Harmening *Université de Genève*
Establishment of an *in vivo* protocol for non-viral gene delivery to ocular tissue

P319

Tae Kwann Park *Soonchunhyang University Hospital Bucheon*
A novel modified deep intravitreal injection improves Adeno-associated virus (AAV)-mediated retinal transduction

First in man

P325

Birgitte Volck *AVROBIO, Inc*
AVR-RD-01 lentiviral gene therapy reduces Gb3 substrate in endothelial cells of renal peritubular capillaries, in a previously untreated classic Fabry male patient

Immune responses to gene therapy

P331

Oumeya Adjali *Inserm UMR1089*
Transgene immunity following AAV-mediated gene transfer to the liver is associated to persisting viral genomes and T cell exhaustion

P333

Irene Ros Gañán *Vivet Therapeutics*
Sensitivity of different AAV serotypes to pre-existing NAbs

P335

Mark Shearman *AGTC*
Neutralizing anti-AAV antibody impact on vector transduction following intravitreal administration of AAV in non-human primates

P337

Kate Lewis *bluebird bio*
A retrospective literature review of the safety outcomes of clinical studies of haemotopoietic stem cell gene therapy using lentiviral vectors in non-oncologic diseases

P339

Gregory Hayes *BioMarin Pharmaceutical*
Treatment with valoctocogene roxaparvovec in a Ph1/2 study (BMN 270-201) elicits cross-reactive antibodies against divergent AAV capsids that exhibit different kinetic profile than anti-drug antibodies.

Poster session I: Wednesday 23 October

P341

Sungho Shin *Seoul National University*
Induction of humoral and cellular immune responses in mice immunized with a DNA vaccine for Zika virus

P343

Elaina Breznau *Charles River Laboratories*
Robust solutions for navigating challenges associated with development and validation of cell-based neutralising antibody assays

P345

Geoffrey Casey *University of Alberta*
Innate immune response of the retinal pigment epithelium to gene therapy vectors

P347

Linas Padegimas *Abeona Therapeutics*
Novel AAV capsids show increased evasion to wild-type AAV9 neutralizing antibodies

P349

R Watano *Jichi Medical University*
Prevalence of NAb against AAV8 in micromini pigs

P351

Sergei Abramov *Kazan Federal University*
Detection of macro-throtropin in patients with Hashimotos Thyroiditis and subclinical hypothyroidism

P353

Marco Zahn *GeneWerk GmbH, Heidelberg*
Evaluation of T- and B-cell receptor diversity using different immune repertoire sequencing methods

iPSC & organoids, research and therapy developments

P355

Steve Pells *ReNeuron*
Scalable allogeneic cell therapies derived by reprogramming inducibly-immortalised adult stem cells

P357

Andres Miguez *University of Barcelona*
In vivo progressive degeneration of Huntington's disease patient iPSC-derived neurons reveals human-specific pathological phenotypes

P359

Jean-Baptiste Dupont *I-STEM*
Single cell developmental trajectories reveal early phenotypes in Duchenne muscular dystrophy prior to skeletal muscle commitment

P361

María Martín López *Andalusian Network for Design and Translation of Advanced Therapies*
Modelling chronic cervical spinal cord injury in aged rats for cell therapy studies

P363

Giulia Raimondi *IDIBAPS*
Patient-derived pancreatic tumor organoids identify therapeutic response to oncolytic adenovirus

P365

Kathrin Haake *Hannover Medical School*
Patient iPSC-derived macrophages to study interferon gamma related pathologies

P367

Tamascia Belardinilli *Bambino Gesù Children's Hospital, Rome*
Innovative 3D model for the establishment of primary paediatric low-grade glioma cultures: New platform for the preclinical study of immunotherapeutic approaches

P369

Silvia Pascual *IDIBAPS*
Establishment of a 3D co-culture model for the study of tumour-stroma interactions in pancreatic ductal adenocarcinoma

P371

Belén Alvarez-Palomo *Banc de Sang i Teixits*
IPS-PANIA project to develop a HLA matched bank of iPSC in Spain

P373

Denise Klatt *Hannover Medical School*
Targeting the AAVS1 locus for genetic correction of p47-CGD in iPSC revealed differential transgene silencing of myeloid-specific promoters

P375

Paul Gissen *UCL Institute of Child Health*
Bioreactor grown iPSc derived hepatocyte-like cells for testing liver directed gene therapy

P379

Ilana Moscatelli *Lund University, Stem Cell Center*
Generation of genetically modified osteoclasts from induced pluripotent stem cells derived from an infantile malignant osteopetrosis patient with a TCIRG1 mutation

P381

Josse Depla *uniQure biopharma B.V.*
Stem cell derived brain organoids, a promising model to study Adeno associated viruses for CNS gene therapy

P383

Louise Bullen *Manchester Metropolitan University*
Interrogation of the molecular role of p62 in iPS reprogramming and maintenance of pluripotency

P385

Andrew Laskowski *Pall Life Sciences*
Pall Xpansion® Bioreactor supports progenitor cell growth to >1 million cells/cm2 and proper cell differentiation

P387

Lucas Blasco Agell *IDIBELL-ICO*
Generation of human microglia-like cells from PD patient-specific iPS cells

Poster session I: Wednesday 23 October

P389

Maria Usik *SSC RF Institute for Biomedical Problems RAS*
The acetylase and deacetylase content in mice ovaries, testes, heart and lung tissues under modeling weightlessness

P391

Akaitz Dorronsoro González *Instituto de Investigación Sanitaria La Fe*
Extracellular vesicles with enhanced immunosuppression capacity secreted by genetically improved mesenchymal stem cells derived from dental pulp

P393

Yoojin Seo *Pusan National University*
Enteroendocrine cell-derived hormone A is involved in the intestinal homeostasis by directing the differentiation of the mouse intestinal organoid

P395

Kirill Sukhinich *Russian Academy of Sciences, Moscow*
Regenerative effects of solid neural tissue grafts located in gelatin hydrogel conduit for treatment of peripheral nerve injury

P397

Marco Luciani *SR Tiget, Milan*
Exploiting targeted epigenetic editing to increase the yield, homogeneity and purity of human iPSC- derived oligodendrocyte cell populations

P399

Marina Rodríguez Rubio *Severo Ochoa Molecular Biology Research Center*
Study of the effect of electrical stimulation in brain development using human brain organoids

P401

Daniel Tornero Prieto *Lund University, Stem Cell Center*
Reconstruction of neuronal network by transplantation of human skin-derived iPS cells after brain stroke

Latest news from cardiovascular and pulmonary gene therapy

P405

Ewa Janosz *RG reprogramming and gene therapy*
Pulmonary macrophage transplantation-based therapy for alpha-1 antitrypsin deficiency

P407

Mauro Giacca *ICGEB, Trieste*
Novel cardioactive factors selected *in vivo* from an AAV library encoding the secret

P409

Eleonora Leggiero *CEINGE-Biotecnologie Avanzate, Napoli*
Muscle expression of a secreted LDLR/Tfchimeric proteinameliorates lipid profile inLDLR-deficient mice

P411

Anastasia Efimenko *Lomonosov Moscow State University*
Decellularized extracellular matrix in modelling lung fibrosis development *in vitro*

Liver gene and cell therapy

P415

Reynald Lescarbeau *Intellia Therapeutics*
In vivo delivery of CRISPR/Cas9 to the liver using lipid nanoparticles enables gene knockout in multiple species

P417

Jooyoung Lee *University of Ulsan College of Medicine*
Differentiation of human liver-derived stem cells into hepatic lineage for therapeutic liver reconstitution

P419

Michela Milani *SR Tiget, Milan*
Targeting of hepatocyte subpopulation contributing to liver post-natal growth is crucial for maintenance of transgene expression in liver-directed gene therapy

P421

Richard Torres *BioMarin Pharmaceutical*
Structural characterization of AAV5-FVIII-SQ vector DNA in human blood by Real-Time and Droplet Digital™ PCR

P423

Qiang (John) Xiong *LogicBio Therapeutics*
Durability of factor IX expression in mice treated neonatally with a nuclease-free, promoterless, AAV-based gene therapy, GeneRide™

P425

Pei She Loh *National University of Singapore, Singapore*
Design, investigation and delivery of advanced trans-splicing RNA for suicide gene therapy

P427

Marta Parés Casellas *Vall d'Hebron Research Institute*
Preclinical assessment of a hepatocyte-directed gene editing approach based on viral vectors and polymeric nanoparticles

P429

Daisuke Kami *Kyoto Prefectural University of Medicine*
Cell therapy for Fabry disease using CellSaic technology

P431

Laia Tolosa *Health Research Institute La Fe (IIS La Fe)*
Human hepatocytes encapsulated in injectable hydrogels for their use in liver cell therapy

P433

Shinnosuke Tsuji *Stanford University*
Elucidating the mechanism of species specificity of recombinant AAV-LK03 transduction

Poster session I: Wednesday 23 October

P435

Lorelei Stoica *Ultragenyx Pharmaceutical*
Using AAV vectors to deliver ATP7B as a treatment for Wilson disease

Metabolic diseases

P441

Marshall Huston *Sangamo Therapeutics*
Liver-targeted AAV gene therapy vectors produced at clinical scale result in high, durable levels of α-GalA enzyme activity and effective substrate reduction in a mouse model of Fabry disease

P443

Sean Armour *Spark Therapeutics*
Pre-clinical development of SPK-3006, an investigational liver-directed AAV gene therapy for the treatment of Pompe disease

P445

Jamie Benoit *Axovant Sciences*
AXO-AAV-GM1 for the treatment of GM1 gangliosidosis: Program overview

P447

Natalia Gomez-Ospina *Stanford University*
Human genome-edited haematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I

P449

Noelia Benetó *University of Barcelona, CIBERER, IBUB, IRSJD, Barcelona*
Novel neuronal and astrocytic models for Sanfilippo C syndrome using CRISPR/Cas9- edited iPSC: Their use in therapeutic approaches.

P451

Giulia De Sabbata *ICGEB, Trieste*
A novel AAV-based therapy in combination with tolerogenic ImmTOR nanoparticles for a sustained treatment of ornithine transcarbamylase deficiency

P453

Lina Li *NHGRI, NIH, Bethesda, MD*
The combination of ImmTOR with AAV Anc80 is therapeutically effective, safe, and repeatable in mice with methylmalonic acidemia while also being compatible with the low seroprevalence of Anc80 Nabs in the patient population

P455

Claudia Jambrina Pallarés *Center for Animal Biotechnology and Gene Therapy*
Skeletal muscle-directed FGF21 gene therapy counteracts obesity and type 2 diabetes

P457

Gloria Gonzalez-Aseguinolaza *Center for Applied Medical Research*
Preclinical validation of radioactive copper excretion as a translational tool for evaluating the pharmacodynamics of gene therapy VTX-801 for Wilson's disease in future first in human

P459

Javier Torres Torronteras *Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona*
The alpha-1-antitrypsin promoter improves the efficacy of an AAV vector for the treatment of MNGIE

P461

Bridget Yates *BioMarin Pharmaceutical*
Phenylalanine hydroxylase (PAH) liver distribution and characterization following AAV5-hPAH gene therapy in Pahenu2 mice

P463

Salih Sanlioglu *Akdeniz University Center for Gene and Cell Therapy*
Lentivirus mediated insulin promoter directed insulin gene expression is effective in suppressing postprandial glucose excursions in Type 1 diabetes

P465

Rocio Maldonado *University of Helsinki*
Gene edited cells in Mitochondrial Recessive Ataxia Syndrome (MIRAS)

P467

Gizem Seker *Akdeniz University Center for Gene and Cell Therapy*
Lentiviral-mediated TRAIL transfer decreased serum alkaline phosphatase, total cholesterol, and glucose levels in high-fat diet-fed obese mice

P469

Zhaochen Shan *School of Stomatology, Capital Medical University*
S1P prevent irradiation induced parotid injury in miniature pig model

P471

Ahter Dilsad Sanlioglu *Akdeniz University Center for Gene and Cell Therapy*
TRAIL increases glucose-stimulated insulin secretion in Min6 cells

P473

Jennifer Ana Pérez Castro *Center of Animal Biotechnology and Gene Therapy*
Long-term correction of visual impairment after AAV-NAGLU-mediated gene therapy in a mouse model of mucopolysaccharidosis type IIIB

Skeletal, muscle & bone gene and cell therapy

P483

Francesco Saverio Tedesco *University College London*
Modulating cell fate determinants for muscle cell therapies: Notch and PDGF signaling enhance stemness and migration of satellite cells and human iPS cell-derived myogenic progenitors

P485

Ignacio Perez de Castro *Instituto de Salud Carlos III*
Study on the therapeutic potential of HITI for the treatment of LMNA-associated congenital muscular dystrophies

Poster session I: Wednesday 23 October

P487

Camille Vaubourg *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Effect of Smad7 gene transfer in a Duchenne muscular dystrophy mouse model

P489

Shelby Hamm *Virginia Tech*
Effects of exercise on the efficacy of microdystrophin gene therapy

P491

Oleg Gusev *Kazan Federal University*
Expression of L-type Ca+2 channels in m. Soleus and m. EDL of rats at early stages of hind-limb unloading and upon their subsequent re-adaptation

P493

Nilakshi Dhananjani Dhanushika Ratnayake *Australian Regenerative Medicine Institute*
Macrophage secreted factors as novel therapeutics to promote stem cell-mediated muscle repair

P495

Penléope Romero Duque *Vall d'Hebrón Institut de Recerca (VHIR), Barcelona*
Development of a novel preclinical gene therapy approach for congenital muscular dystrophy 1A

P497

Alina Cequier Soler *University of Zaragoza*
Humoral immune response against allogeneic equine mesenchymal stem cells (MSCs) mediated by the major histocompatibility complex (MHC): An issue to take into account for the safety and efficacy of treatment with MSCs

P499

Ilnur Ishmukhametov *Kazan Federal University*
Differentiation potential of stem cells cultured on glass surfaces coated with magnetic nanoparticles

P501

Viktorija Cernisova *Royal Holloway, University of London*
Periostin splice variant expression in skeletal muscle fibrosis and effective anti-fibrotic action of antisense oligonucleotides that block periostin expression

P503

Ivan Yakovlev *Human Stem Cells Institute, Moscow*
Assessment of exon-skipping feasibility for treatment of dysferlinopathy

P505

Nastasia Kosheleva *FSBSI Institute of General Pathology and Pathophysiology, Moscow*
Mesenchymal stem cells from gingiva as a new source of autologous myogenic progenitors

P507

Yong-Gun Kim *Kyungpook National University*
Visualization of woven bone structure through analysis of biopsy specimens using synchrotron radiation and conventional X-ray micro-CT

P509

Olga Chernova *Kazan Federal University*
Histopathological analysis of gingiva-derived MMSCs transplantation effect on skeletal muscles regeneration

P511

Ying Zheng *Capital Medical University*
Evaluation of collagen membrane as a pulp capping agent in swine

P513

Ilnur Ishmukhametov *Kazan Federal University*
Chondrogenesis of stem cells on substrate coated with magnetic nanoparticles

P515

Maria Boldyreva *Russian Ministry of Health, Moscow*
Adipose stromal cell sheet producing hepatocyte growth factor (HGF) effectively stimulates recovery of ischemic skeletal muscle in mouse hind limb ischemia model

P517

Lijia Guo *Capital Medical University*
microRNA 21 promotes orthodontic tooth movement via TNF-alpha/ RANKL pathway in T cells

P519

Artur Fedianin *Kazan Federal University*
The rat skeletal muscle under the simulated weightlessness

P525

Anastasia Efimenko *Lomonosov Moscow State University*
Diversity of mesenchymal stromal cells: Secretome in focus

Skin gene and cell therapy

P531

Ai-Li Shiau *National Cheng Kung University Medical College*
Knockdown of prothymosin α improves wound healing in diabetic mice

P533

Rodolfo Murillas Angoiti *Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz IIS-FJD*
Preclinical models for *in vivo* gene editing of COL7A1 based on delivery of CRISPR/Cas9 to RDEB patient skin by adenoviral vectors

P535

Araksya Izmiryan *INSERM UMR 1163, Imagine Institute, Paris*
CRISPR/Cas9-mediated correction of two recurrent COL7A1 mutations in primary and induced pluripotent stem cells from patients with recessive dystrophic epidermolysis bullosa

Poster session I: Wednesday 23 October

P537

Nataliya Basalova *Institute foLomonosov Moscow State University*
Extracellular vesicles secreted by mesenchymal stromal/stem cells reverse TGF-β induced myofibroblast differentiation

P539

Anastasia Efimenko *Lomonosov Moscow State University*
Antifibrotic effect of mesenchymal stromal cell sheets is mediated by interaction of stromal and endothelium cells

P541

Christine Baldeschi *I-STEM*
Production of clinical grade temporary epidermal substitute obtained from hESC derived keratinocytes for the treatment of sickle cell leg ulcers: a challenge for regenerative medicine

P543

Leire Gardeazabal *I.I.S. Biodonostia*
Human breast milk exosomes accelerate mouse wound healing

New approaches in gene editing

P549

Asael Herman *Emendo Biotherapeutics*
Target optimized variant of CRISPR associated nuclease enables allele-specific knock out of ELANE-related neutropenia

P551

Sara Fañanás Baquero *CIEMAT / CIBERER, Madrid*
Efficient gene editing of the PKLR locus in human long-term haematopoietic stem cells to correct Pyruvate Kinase Deficiency

P553

Andreas Neerincx *Bayer AG Preclinical Research, Protein Engineering, Cologne*
Engineering of small and potent synthetic RNA-guided cytosine base editors

P555

Oscar Quintana Bustamante *CIEMAT / CIBERER, Madrid*
Highly precise gene editing correction of a Pyruvate Kinase deficiency-causing mutation in patient-derived lymphoblastic cells using single stranded oligodeoxinucleotides

P557

Yongxing Fang *University of Freiburg*
Chimerization enables effective delivery of TALE-based effectors by lentiviral vectors

P559

Beatrice Claudia Cianciotti *San Raffaele Scientific Institute, Milan*
LAG-3, but not Tim-3, disruption in TCR gene edited human memory stem T cells enhance the anti tumor activity against multiple myeloma

P561

Simone Haas *University of Freiburg*
Abnoba-seq: A sensitive *in vitro* assay to profile CRISPR-Cas nuclease off-target activity in a truly unbiased manner

P563

Mollie Schubert *IDT*
Improved methods for CRISPR HDR using Alt-R HDR Enhancer and modified ssDNA donors with optimized design

P565

Aurelien Jacob *SR Tiget, Milan*
Cell cycle "push-up" to boost targeted genome editing in haematopoietic stem cells

P567

Suki Roy *Nanyang Technological University, Singapore*
A novel λ integrase-mediated transgenesis platform for biologics production

P569

Florine Samain *Flash Therapeutics*
All-in-one delivery using LentiFlash technology, a MS2-chimeric RNA delivery tool designed for clinical applications

P571

Stefania Crippa *SR Tiget, Milan*
Mesenchymal stromal cell support to optimize HSPC-gene editing

P573

Roberto Nitsch *AstraZeneca, Biopharmaceutical R&D*
Assessment of the tumorigenicity potential of CRISPR/Cas9 genome editing using an innovative *in vitro* cellular transformation assay

P575

Natalia Gomez-Ospina *Stanford University*
Engineering monocyte lineage-specific glucocerebrosidase expression in human haematopoietic stem cells using genome editing: A universal strategy for genetic correction in Gaucher disease

P577

Duran Sürün *Dresden University*
Base editors-mediated generation of point mutations in IPS cells

P579

Araceli Aguilar González *GENyO*
Generation of cellular models to study gene therapy strategies for Pompe disease

P581

Marta Zinicola *Institute of Child Health*
Targeted gene insertion for the treatment of X-linked agammaglobulinemia (XLA)

P583

Amy Walker *University College London*
Nanoparticle delivery of CRISPR/Cas9 for treatment of cystic fibrosis by homology independent targeted integration

Poster session I: Wednesday 23 October

P587

Virginia Arechavala *Biocruces Bizkaia Health Research Institute*
A CRISPR/Cas9 edition protocol for human myoblasts to generate disease models

P589

Lucrezia Della Volpe *Universita Vita-Salute San Raffaele*
Cell cycle dependent activation of a pro-inflammatory transcriptional program in Haematopoietic Stem and Progenitor cells (HSPCs) in response to DNA damage

P591

Dawid Glow *University Medical Center Hamburg-Eppendorf*
Novel cell-based assays for the assessment of potential toxic effects of CRISPR/Cas9 genome editing

P593

Maria Schacker *Biopharma Excellence*
From fiction to science: Clinical potentials of gene editing

P595

Gaurav Agrahari *Catholic University of Korea*
Superoxide dismutase 3 augments survival rate of mesenchymal stem cells in the nutritionally stressed condition

P601

Deya Corzo *Sigilon Therapeutics*
Correcting bleeding disorders using blood clotting factors produced *in vivo* by shielded engineered allogeneic cells

P603

Youna Coquin *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Lentiviral vectors pseudotyped with murine syncytins efficiently transduce B cells *in vitro* and *in vivo*

New delivery systems

P605

Branden Moriarity *University of Minnesota*
Engineered B cells as a universal platform for the treatment of enzymopathies

P607

Emilie Audouard *INSERM U1127 - NEUROGENCELL - Eq Cartier*
Therapeutic approach for multiple sclerosis using a bioelectronic cell implant

P609

Anne Galy *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Human endogenous retroviral envelope glycoproteins syncytin-1 and syncytin-2 enable effective lentiviral transduction of human primary B cells and dendritic cells

P611

Daniel Veilleux *EnGene Inc*
Development and pre-clinical characterization of an oral solid dosage formulation for gene delivery to intestinal mucosa

P613

Cristina Fornaguera *Institut Quimic de Sarria*
Poly(beta aminoester) nanoparticles encapsulating mTOR siRNA for lung cancer therapy

P615

Christopher Thornton *Manchester Metropolitan University*
Safer and more stable iPSC generated using Doggybone DNA vectors

P617

Robin Stiener *Ulm University*
Enabling efficient transduction of mesenchymal stromal cells by HAdV-5-based vectors

P619

Yumiko Komatsu *Kyoto University*
In vivo evaluation of replication competent and defective RNA-virus based episomal vector system

P021

Alicia Rodríguez Gascón *University of the Basque Country UPV/EHU*
Effect on alpha-Gal A activity of short-term systemic therapy with a solid lipid nanoparticle based non-viral vector in a knockout mouse of Fabry disease

P623

Heleen van der Veen *Utrecht University*
Microfluidic ynthesis of ionizable lipid nanoparticles containing CRISPR/Cas9 ribonucleoprotein complexes

P625

Sofia Shtykalova *Laboratory of Molecular Genetics and Gene Therapy, Saint-Petersburg*
Suicidal gene therapy of leiomyoma via delivery of herpes thymidine kinase gene by means of αvβ3 integrin-targeted peptide-based nanoparticles

P627

Albert Rizvanov *Kazan Federal University*
Recombinant plasmids containing picornaviral self-cleaving 2A-peptides and expressing VEGF and FGF2 growth factors induce angiogenesis *in vivo*

P629

Ezgi Oner *Ege University, Izmir*
Evaluation of the cationic solid lipid nanoparticles carrying siRNA against EphA2 receptor as non-viral delivery systems

P631

Franziska Hausig *Friedrich Schiller University Jena*
Novel non-toxic polymers for overcoming the endosomal barrier

P633

Shauna Dauphinee *EnGene Inc*
Optimization of a nanoparticle gene delivery system for intravesicular delivery of DNA to bladder mucosa

P635

Matt Krusen *Aldevron*
mRNA synthesis reagents and manufacturing: Research through clinical development

P637

Gilta Jaeckel *Charles River Laboratories*
Validation of a relative standard curve RT-qPCR method for the measurement of a therapeutic microRNA in plasma and tissue samples

P639

Busra Cesur *Akdeniz University Center for Gene and Cell Therapy*
Development of nano-sized non-viral DNA delivery system for gene therapy purposes

P641

Ilnur Ishmukhametov *Kazan Federal University*
Magnetically modified halloysite nanotubes - nanocontainers for drugs

P643

Ilnur Ishmukhametov *Kazan Federal University*
Selective DNA-damaging activity of curcumin@halloysite nanoformulation

P645

Maxim Baltin *Kazan Federal University*
Effect on the electrical characteristics of spontaneously active neurons of the visceral ganglion of the nervous system of the mollusk Helix lucorum

P647

Diana Sabirova *Kazan Federal University*
Evaluation of methylprednisolone delivery to nerve tissue using polymer conjugates in spinal cord injury in rats

P649

Ilnur Ishmukhametov *Kazan Federal University*
Relationship between oil-degrading bacteria Alcanivorax borkumensis and nematode Turbatrix aceti

Regulatory session

P655

Daniel O'Connell *Intellia Therapeutics*
In silico, biochemical and cell-based integrative genomics identifies precise CRISPR/Cas9 targets for human therapeutics

P657

Shih-Yao Chen *National Cheng Kung University Medical College*
Galectin-3 as a NETosis mediator in systemic lupus erythematosus

P659

Sheridan Sarah *Merck Millipore*
Biosafety testing of cell and gene therapies; rapid methods and regulatory expectations

P661

Carolina Iglesias-Lopez *Universitat Autònoma de Barcelona*
Hurdles of environmental risk assessment procedures for advanced therapies medicinal products

P663

Florian Durst *Thermo Fisher Scientific*
Streamlined high performance extraction and quantitation of host cell residual DNA

P665

Joel Montané Mogas *Asphalion*
Regulatory and nonclinical considerations for translation of gene therapy medicinal products to first-in-human clinical trials

P667

Elisabet Aguilar *Andalusian Network for Design and Translation of Advanced Therapies*
Scalability strategies for cell manufacturing

P669

Katie Snell *UCL Institute of Child Health*
Developing a standard operating procedure for clinical trial advanced therapy investigational medicinal product administration; a single centre experience

Other

P671

María Rosario Hervás Salcedo
CIEMAT / CIBERER, Madrid
Enhanced anti-inflammatory properties of human mesenchymal stromal cells by transient co-expression of CXCR4 and IL-10

P673

Yen-Hui Chan *Taichung Tzu Chi Hospital*
Transcriptomic characterization and gene therapy of balancing dysfunction in Slc26a4-defected mice

P675

Esther López *Centro de Cirugía de Mínima Invasión Jesús Usón*
Bone marrow mesenchymal stem cells accelerate wound healing after hernia repair with polypropylene surgical meshes

P677

Natalia Izotova *UCL Institute of Child Health*
De novo production of genetically engineered T cells is maintained in humans decades after loss of transplanted haematopoietic stem cells.

P679

Luca Del Core *SR Tiget, Milan*
A novel Bayesian regression framework highlights dependences of clonal dynamics on different vector designs in *in vivo* gene therapy studies

P681

Fabrizio Benedicenti *SR Tiget, Milan*
Sonication Linker Mediated-PCR (SLiM-PCR), an efficient method for quantitative retrieval of vector integration sites

P683

Mercedes Lopez-Santalla *CIEMAT / CIBERER, Madrid*
Cell therapy with adipose-derived mesenchymal stromal cells alters the endogenous trafficking of myeloid populations *in vivo*

Poster session I: Wednesday 23 October

P685

Qingsong Jiang *Beijing Stomatological Hospital, Capital Medical University*
Depletion of PTN inhibits the osteogenic differentiation potential of dental pulp stem cells

P687

Esther López *Centro de Cirugía de Mínima Invasión Jesús Usón*
The inflammation mechanisms in myocardial infarction are altered after intrapericardial administration of cardiosphere-derived stem cells and their extracellular vesicles.

P689

Esther López *Centro de Cirugía de Mínima Invasión Jesús Usón*
Intrapericardial administration of Cardiosphere Derived Cells early after experimental myocardial infarction in swine: safe, easy but of limited effectiveness.

P691

Tobias Wimmer *Justus-Liebig University Giessen*
A bioluminescence resonance energy transfer based sensor for the precise determination of non-homologous end joining DNA repair events

P693

Anastasia Efimenko *Lomonosov Moscow State University*
Mesenchymal stromal cell secretome as a promising tool for male infertility treatment

P695

Chao-Liang Wu *National Cheng Kung University Medical College*
Silencing of prothymosin α as a therapeutic strategy for the treatment of polycystic kidney disease

P697

Estefania Rodriguez *CIMA, Universidad de Navarra*
AdrA as a potential immunomodulatory candidate for STING-mediated anti-viral therapy

P699

Seung Bin Yoon *Korea Research Institute of Bioscience & Biotechnology (KRIBB)*
Reference values of haematological and biochemical parameters in young-adult cynomolgus monkey (Macaca fascicularis) and rhesus monkeys (Macaca mulatta) nesthetized with ketamine hydrochloride

P701

Regina Kashapova *Kazan Federal University*
Creation of technology for manufacturing composite titanium polymer implants

P703

Yi Liu *Capital Medical University*
Low-level laser enhances gingival wound healing through promoting migration of human gingival mesenchymal stem cells via ROS/JNK/NF-κB/MMP-1 pathway

AAV vector development

P002

Kalyani Nambiar *University of Pennsylvania Perelman School of Medicine, Philadelphia*
Transduction evaluation of novel AAV natural isolates in nonhuman primates using a barcoded transgene system

P004

Diana Cepeda *Adverum Biotechnologies Inc., Menlo Park, California, USA*
In vivo screening of an adeno-associated virus capsid library in non-human primate eyes identifies a novel AAV variant with superior retinal penetration and transduction by intravitreal delivery

P006

Marti Cabanes-Creus *Children's Medical Research Institute*
Modulating the heparan sulfate proteoglycan binding of AAV2 enhances *in vivo* transduction of human hepatocytes in a xenograft mouse model

P008

Waldemar Schäfer *University Medical Center Hamburg-Eppendorf*
Nanobody-enhanced targeting of AAV vectors

P010

Claus Hallwirth *Children's Medical Research Institute*
Nature trumps nurture: Use of naturally liver-tropic adeno-associated viruses as vector platforms for liver-directed human gene therapy

P012

MatthewFuller *Ultragenyx Pharmaceutical*
Characterization of HPV-related impurities in HeLa producer cell line generated rAAV and *in vivo* preclinical analysis of HPV-related host cell DNA persistence and gene expression following vector delivery

P014

Simon Chanas *GlaxoSmithKline*
Over-expression of the E. coli single stranded DNA binding protein (ssb) inhibits the loss of Adeno-associated virus (AAV) hairpin loop inverted terminal repeats in transfer vector plasmid preps

P016

Hong You *Beijing Friendship Hospital, Capital Medical University*
Casein kinase 2 phosphorylates Rep78 of adeno-associated virus (AAV) type 2 Rep78 with effects upon its biochemistry and boosts AAV replication

P018

Nicholas Buss *REGENXBIO Inc.*
AAV9.hCLN2 (RGX-181) improves survival and neuropathology in TPP1m1j mice, a model for CLN2 Batten disease

P020

Elena Iurlova *Biotechnology company BIOCAD, Saint-Petersburg, Russia*
Optimization of elution conditions for immunoaffinity chromatography of AAV5 and AAV9 vectors

P022

Axel Rossi *Hannover Medical School, Hannover, Germany*
Capsid engineering overcomes barriers toward Adeno-associated viral (AAV) vector-mediated transduction of endothelial cells

P024

Mathieu Mevel *INSERM UMR 1089, University of Nantes, CHU de Nantes, Nantes*
Chemically modified AAV vectors for gene therapy

P026

Esther Attebi *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Development of purification step for several AAV serotypes using POROS™ CaptureSelect™ AAVX affinity chromatography

P028

Roman Raim *Baxalta, a Takeda company*
Critical aspects in implementing a precise and reliable droplet digital PCR method as dose measurement assay for determining vector genomes in rAAV- based Gene Therapy products

P030

Huseiyin Besir *PROGEN Biotechnik GmbH*
The new AAV3 Titration ELISA – continued tradition of reliable AAV titer determination

P032

Akihiro Kume *Jichi Medical University*
Adeno-associated virus (AAV) serotype 3-based vector as an alternative vehicle for liver-directed gene therapy

P034

Eva Reinauer *Leukocare AG*
Effective stabilization of viral vectors in liquid using an algorithm-based development approach

P036

Nihay Laham Karam *A.I. Virtanen Institute, University of Eastern Finland*
Enhanced Adeno-associated virus transduction in endothelial cells

Viral vectors manufacturing

P040

Weiheng Su *University of Oxford*
Self-repressing 'helper' adenovirus enabled efficient manufacture of adeno-associated viral vectors without contamination by adenovirus or small drugs

P042

Lorella Tripodi *SEMM-European School for Molecular Medicine, Napoli, Italy*
Synergistic effect of combined administration of an oncolytic adenovirus and Bifidobacterium spp. supplements in a mouse model of melanoma

Poster session II: Thursday 24 October

P044

Martin Busch *Heidelberg University Hospital*
Impact of production impurities on potency of Adeno-associated virus vectors: Systematic comparison of density gradient and affinity purification

P046

Eduard Ayuso *INSERM UMR1089, University of Nantes, CHU de Nantes, Nantes*
Automated HEK293 suspension cell adaptation to new media and use of new DoE approach to optimize AAV production in suspension utilizing the ambr®15 platform

P048

Qian Liu *Oxford Genetics Ltd*
Scalable and high-titre lentiviral vector production from cGMP-compliant clonal suspension HEK293 cell line

P050

Eric Faulkner *Homology Medicines Inc*
Impact of full and empty particle concentration on product quality and *in vivo* efficacy of HMI-102 in a mouse model of phenylketonuria

P052

Pranav Joshi *McGill University, Quebec, Canada*
Chromatographic approach for separation of AAV capsid variants

P054

Isobel Searing *Oxford BioMedica*
Analytical development and automation of lentiviral vectors

P056

Joseph Zeguer *Orchard Therapeutics PLC*
A BAC-cloning platform for development of stable producer cell lines for commercial scale lentiviral vector manufacture

P058

Dina Glazkova *Center for Strategic planning and management of medical and biological risks, Russian Federation*
Interposition of genes in anti-HIV lentiviral vector affects its titer and antiviral activity

P060

Jian Gao *Witten/Herdecke University*
Improved delivery of tumor specific oncolytic adenovirus type 5 with NK-92 carrier cells in cancer treatment

P062

Thomas Williams *Oxford BioMedica*
Industrial Lentiviral vector manufacturing using advanced process analytical technologies

P064

Ana S. Coroadinha *iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal*
Enabling stable lentiviral vector producer cell line generation: Identifying barriers to high productivities

P066

Man Sub Kim *Osong Medical Innovation Foundation*
Application of the design of experiment method for AAV vector production in suspension cells

P068

Cristina Salado Manzano *University of Barcelona, Barcelona, Spain*
Innovative cell-based therapy to treat Huntington's Disease

P070

Marie Jourdan *Univercells*
Scalable single-use technology to meet gene therapy & vaccines production demands

P072

Annu Luostarinen *Research & Development, Finnish Red Cross Blood Service, Helsinki, Finland*
Comparative analysis of lentiviral vector final formulation conditions for the *ex vivo* transduction of primary human T-cells

P074

Eva Fong *Merck Millipore*
Development and scale-up of a bench-scale bioreactor process for transient lentivirus production using a suspension-Adapted HEK293T clone

P076

Juan Carlos Ramirez *VIVEbiotech*
SerLess: An adherent HEK293-derived producer cell line for manufacturing lentiviral vectors in the absence of animal-derived serum

P078

Emmanuelle Cameau *PALL Biotech*
Cost modeling comparison of static, suspension and fixed-bed bioreactors to manufacture commercial gene therapy products

P080

Matt Krusen *Aldevron*
Advantages of standardization and large-scale manufacturing of helper plasmids for viral vector production

P082

Joëlle Cheuzeville *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Improvement of lentivirus manufacturing in large-scale bioreactors using PTG1plus, a novel cationic transfection agent, in suspension HEK 293T cells

P084

Miguel Chillon *Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain*
UPV: Production of customized high quality viral vectors at the joint UAB-VHIR technological platform

Poster session II: Thursday 24 October

P086

Ram Shankar *PlasmidFactory GmbH & Co. KG*
RNase-PF: An animal-free recombinant solution for the removal of host-cell RNA

Cancer

P090

Els Verhoeyen *EVIR/CIRI/INSERM U1111, Lyon*
Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector: A new tool for CAR NK cell immunotherapy

P092

Simona Porcellini *MolMed S.p.A*
GMP grade CD44v6 CAR-engineered T cells control tumor growth in lung and ovary adenocarcinoma bearing mice

P094

Katharina Bergerhoff *GammaDelta Therapeutics*
Human Vδ1+ T cells; an allogenic 'off-the shelf' T cell therapy platform

P096

Leysan Minigulova *Kazan Federal University, Kazan, Russia*
Transmembrane topogenesis and folding of extramembrane domains of NaPi2b transporter under conditions of malignant transformation can lead to the appearance of tumor-specific epitopes

P098

Julia Davydova *University of Minnesota*
Pigs versus rodent models for assessing performance of serotype chimeric Ad5/3 oncolytic adenoviruses

P100

Juan José Rojas Expósito *Ludwig-Maximilians-Universitat München*
Induction of immunogenic tumor cell death by a novel immune-oncolytic Vaccinia virus strain leads to robust antitumor immune responses directed against neo-epitopes

P102

Estela Núñez Manchón *IDIBAPS*
Transgene codon usage adaptation, a novel strategy for the design of armed oncolytic adenoviruses

P104

Julia Serna *IBGM - University of Valladolid*
New gene-editing strategy for allogeneic NKG2D-CAR T cell production

P106

Daniel Blount *Oxford BioMedica*
Pre-clinical proof-of-concept for CAR-T Cells directed against the tumour antigen 5T4 in the treatment of haematological malignancies

P108

Reem Miari *University of Haifa*
miRNA-193a function as a tumor suppressor gene in human head and neck cancer: Development of a novel therapeutic strategy

P110

Alexandra Mowday *Maastricht University*
Targeting the tumour microenvironment with anaerobic bacteria

P112

Berta Marzal *Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)*
Low-affinity Her2-specific CAR-T cells for the treatment of breast cancer

P114

Olga Trofimova *Latvian Biomedical Research and Study centre*
Alphavirus-driven expression of IFNgamma as a potential strategy for programming of tumour macrophages

P116

Alvaro Morales-Molina *Instituto de Salud Carlos III*
Cellular virotherapy increases tumor-infiltrating lymphocytes (TILs) and CD8+ activation in murine immunocompetent models

P118

Lukasz Kuryk *Targovax Oy, Clinical Science, Helsinki, Finland*
Combinatory therapy of the oncolytic adenovirus ONCOS-102 and checkpoint inhibitor resulted in abscopal anti-tumor effect in a humanized NOG mouse model of melanoma

P120

John Rossi *Kite, a Gilead Company*
Analysis of T-cell vector integration sites for a murine gamma-retroviral vector encoding the anti-CD19 chimeric antigen receptor used in the production of axicabtagene ciloleucel

P122

Bernhard B Gentner *San Raffaele Scientific Institute*
TEM-GBM-001 study: A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched haematopoietic progenitor cells genetically modified for human interferon-α2 in patients with GBM and an unmethylated MGMT promoter

P124

Laura Antonucci *Bambino Gesù Children's Hospital, Rome - Italy*
Innovative strategy to potentiate oncolytic adenovirus immunotherapy in high-risk neuroblastoma

P128

Seung Ryul Han *Rznomics Inc.*
RNA replacement based on trans-splicing ribozyme for cancer theranostics

P130

Noelia Silva Pilipich *Cima Universidad de Navarra, Pamplona, Spain*
Long-term systemic expression of a new PD-1 blocking antibody from an AAV vector provides antitumor activity without toxicity

Poster session II: Thursday 24 October

P132

Daria Chulpanova *Kazan Federal University, Kazan, Russia*
An immunocompetent mouse model of human neuroblastoma

P134

Lukas Schulte *Witten/Herdecke University, Witten, Germany*
Screening of reporter gene expressing human adenovirus types with regard to their use in oncolytic/cancer gene therapy against HPV associated cancers

P136

Alvaro A Morales-Molina *Instituto de Salud Carlos III*
Modifications in the RGD motifs of an oncolytic adenovirus (ISC301) increases its antitumor efficacy by a higher intratumoral activation of the immune system

P138

Wen-Lung Wang *National Cheng Kung University*
Elucidating transcriptional roles in the regulation of IMP3 expression for developing promoter-driven targeted therapy in hepatocellular carcinoma

P140

Stephanie Riederer *Ludwig-Maximilians-Universitat München*
Deletion of Vaccinia virus genes involved in the blocking of TRIF-IRF3-pathway and its effect on Th1-polarized antitumor immune responses

P142

Jiye Kim *University of Ulsan College of Medicine*
Synergistic anticancer therapeutic effect of sorafenib and microRNA-21 inhibitor in Hepatocellular carcinoma

P144

Aigul Valiullina *Kazan Federal University, Kazan, Russia*
Evaluating CAR-T cells efficiency against solid tumors models

P146

Kristina Kitaeva *Kazan Federal University*
The effect of co-culturing of MSC and SH-SY5Y and cisplatin treatment on proliferative activity and caveolin-1 mRNA expression

P148

Ilnur Ishmukhametov *Kazan Federal University, Kazan, Russia*
Hyperspectral system imaging for detection of cancer cells

P150

Daria Chulpanova *Kazan Federal University, Kazan, Russia*
Antitumor properties of artificial microvesicles from mesenchymal stem cells overexpressing TNF-related apoptosis inducing ligand

P152

Eva Aubets Gil *University of Barcelona*
WEE1 and CHK1 gene silencing using polypurine reverse hoogsteen hairpins

P154

Yeon-Soo Kim *Chungnam National University*
Replicating retroviral vectors spread on the human retinoblastoma SNUOT-Rb1 cells and induce cell death

P156

Gulzada Tarasova *Kazan Federal University, Kazan, Russia*
Dissipation of the transmembrane mitochondrial potential in malignant tumor cells by water-soluble polyol-methanofullerene

P158

Ilnur Ishmukhametov *Kazan Federal University, Kazan, Russia*
Comparative analysis of mechanical properties of non-malignant and cancer cells

P160

Manlio Fusciello *University of Helsinki*
Artificially cloaked viral nanovaccine

Next generation engineered T&NK cells

P162

Birgit Schultes *Intellia Therapeutics*
Engineering of highly functional and specific transgenic T cell receptor (TCR) T cells using CRISPR-mediated in-locus insertion combined with endogenous TCR knockout

P164

Asier Antoñana Vildosola *IDIBAPS*
Engineering BCMA-CAR T cells to overcome CD19-negative relapse in B cell non-Hodgkin lymphomas

P166

Junghee Kim *Korea University College of Medicine, Seoul, South Korea*
TEM8/ANTXR1-targeting CAR-T cells as a therapeutic modality for the pancreatic cancer

P168

Maria Alvanou *University of Patras Medical School*
Broadening the applicability of antigen-specific T-cell immunotherapy by CRISPR-CAS9 inactivation of the glucocorticoid receptor

P170

Biagio De Angelis *Ospedale Pediatrico Bambino Gesù- Rome- Italy*
A promising approach of GD2-specific chimeric antigen receptor (CAR) T cells with CD28/4.1BB costimulatory domains for treatment of GD2+ sarcomas

P172

Corinna Haist *Heinrich Heine University Dusseldorf*
Specificity and efficacy of second generation CAR T-cells against CD44v6 antigen in primary HNSCC cells

P174

Bilge Debelec Butuner *Technical University of Munich, Germany*
Comparing the functionality of redirected T cells in HBV immunotherapy using chimeric antigen receptors or T-cell engaging antibodies

P176

Ralf-Holger Voss *Johannes Gutenberg University (JGU), Mainz, Germany*
A combinatory CAR relying on T-cell signaling via endogenous CD3 elicits paramount tumor antigen sensitivity via retrovirally, ivt-RNA-, or CRISPR/Cas9 NHEJ/HDR-treated human T-cells

P178

Noelia Maldonado Pérez *GENyO*
Assessment of efficacy and safety of universal αCD19-CAR T cells

P180

Jeong-Soo Kim *University College of Medicine, Seoul, Republic of Korea*
Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients

P182

Sumiti Jain *Sangamo Therapeutics, Inc.*
Highly efficient and specific multiplexed gene editing in T cells using enhanced zinc-finger nucleases (ZFNs) enables strategic engineering of allogeneic T cell immunotherapies

P184

Quentin Vicard *Sartorius Stedim Biotech*
Optimizing CAR-T process development by utilizing a novel small scale stirred tank bioreactor

P186

Geert Nobels *MaxCyte*
Advancing adoptive cellular therapies using non-viral-based engineering

P188

Gus Zeiner *Chimera Bioeignieering*
A new approach to arm T cell therapies with conditional, transgenic payload outputs

Blood diseases

P196

Mo Li *King Abdullah University of Science and Technology*
Wiskott-Aldrich syndrome protein tegulates nuclear body organization, chromatin structure, alternative splicing and cell proliferation

P198

Desheng Liang *Center for Medical Genetics Central South University, Changsha, China*
Targeted in-frame deletion of the F8 B domain to restore FVIII function in patient-iPSCs derived ECs

P200

Yu-zhen Tan *Shanghai Medical School of Fudan University*

Cardiac patch loading Tβ4-overexpressed mesenchymal stem cells promotes repair of infarcted myocardium by activating epicardium

P202

Pamela Quaranta *SR-TIGET, Milan*

Role of peripheral blood circulating haematopoietic stem/progenitor cells during physiological haematopoietic maturation and after gene therapy

P204

Aphrodite Georgakopoulou *University of Washington, Seattle, USA*

In vivo transduction of HSCs in a Fanconi anemia mouse model after mobilization and intravenous injection of an integrating adenoviral vector system

P206

Vanessa Woods *Hannover Medical School, Hannover, Germany*

Targeting therapeutic proteins to platelet alpha granules

P208

Guillaume Corre *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*

Induction of DNA methylation in CD34+ cells during *ex vivo* genetic modifications

P210

Marianna Romito *Institute of Child Health*

Targeted gene correction for the treatment of severe combined immunodeficiency caused by mutations in the IL7R gene

P212

Luca Basso-Ricci *SR-TIGET, Milan*

Kinetics and composition of haematopoietic stem/progenitors mobilised cells upon G-CSF and Plerixafor administration in transplant donor or patients undergoing autologous gene therapy

P214

Immacolata Brigida *SR-TIGET, Milan*

Preclinical development of a haematopoietic stem cell gene therapy for adenosine deaminase 2 deficiency

P216

Mania Ackermann *Hannover Medical School, Hannover, Germany*

Restored macrophage function ameliorates disease pathophysiology in a mouse model for very early onset inflammatory bowel disease (VEO-IBD)

P218

Hristiana Lyubenova *Telethon Institute of Genetics and Medicine*

AAV-mediated protein trans-splicing and genome editing for therapy of Haemophilia A

Poster session II: Thursday 24 October

P220

Begoña Diez Cabezas *CIEMAT/CIBERER, Madrid*

Optimized manufacturing of lentiviral corrected haematopoietic stem cells under GMP conditions

P222

Kyriakos Koukoulias *George Papanicolaou Hospital, Thessaloniki, Greece*

LEVIS: A clinical scale, "all in one" T-cell product from non-transplantable cord blood units, targeting infections and leukemic relapse post-haematopoietic cell transplantation

P224

Ekaterina Koniaeva *Hannover Medical School, Hannover, Germany*

Conditional immortalisation of haematopoietic progenitors via tetracycline-regulated LMO2 expression

P226

Diego Leon-Rico *UCL GOS Institute of Child Health*

Manufacture of an ATMP for the treatment of X-linked Severe Combined Immunodeficiency (X-SCID)

P228

Cristina Mesa *CIEMAT/CIBERER, Madrid*

Stable transduction of long-term HSCs under optimized GMP-conditions for the gene therapy of LAD-I patients

P230

Carsten W Lederer *Cyprus Institute of Neurology and Genetics*

Getting personal: Mutation-specific gene editing and addition strategies for β-thalassemia and beyond

P232

Blanca Quijano Ruiz *Andalusian Network for Design And Traslation of Advanced Therapies*

Treatment of steroid refractory acute graft-versus-host disease with allogenic adipose tissue-derived mesenchymal stromal cells: A multicenter phase I/II clinical trial

P234

Juan A. Hernandez Bort, PhD *Gene Therapy Center Austria, Baxalta Shire*

Impact of selected cell culture media and different HEK293 production cell lines on the expression of a variety of recombinant adeno associated virus subtypes

P236

Elena Armenteros Monterroso *Great Ormond Street Hospital for Children*

Comparison of the CliniMACS Plus and the CliniMACS Prodigy for CD34 enrichment of mobilised peripheral blood stem cells (mPBSC)

P240

Maria Grazia Biferi *Sorbonne Université, Inserm UMRS 974, Institut de Myologie*

Towards the clinical translation of a gene therapy approach for the treatment of familial ALS

CNS gene therapy

P242

José María Frade *Instituto Cajal (CSIC)*
E2F4-based gene transfer improves learning and memory and reverses body weight loss in a mouse model of Alzheimer's disease

P244

Kevin Foust *AveXis, Inc.*
Rett syndrome gene therapy improves survival and ameliorates behavioral phenotypes in MeCP2 null

P246

Rod Miller *University of Pennsylvania*
Preclinical evaluation of gene therapy for neurodegenerative diseases caused by inherited deficiency of progranulin

P248

Rebeca Blanch *Institut de Neurociències - Universitat Autònoma de Barcelona*
Klotho gene therapy as a treatment for Alzheimer's disease

P250

James M Wilson *University of Pennsylvania, Perelman School of Medicine, Philadelphia*
Intrathecal gene therapy significantly extends lifespan of the Twitcher mouse and the Krabbe dog models

P252

Ilaria Meloni *Medical Genetics, University of Siena, Siena, Italy*
High efficiency of CRISPR/Cas9 gene editing of the p.(Thr158Met) MECP2 mutation in mitotic and post-mitotic cells

P254

Vania Broccoli *San Raffaele Scientific Institute*
Whole brain delivery of an instability-prone Mecp2 transgene corrects behavioral and molecular pathological defects in mouse models of Rett syndrome

P256

Stefano Espinoza *Istituto Italiano di Tecnologia*
SINEUPs: A new antisense, long non-coding RNA-based platform to increase endogenous protein levels for therapy

P258

Catherine Marneffe *VIB-KU Leuven Center for Brain & Disease Research*
AAV-mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer's disease mouse model

P260

Joao Cruzeiro *Sheffield Institute for Translational Neuroscience*
AAV-mediated gene editing as a potential therapeutic approach for C9ORF72-linked ALS/FTD

P262

Ángela Sánchez Osuna *Universitat Autònoma de Barcelona, Bellaterra, Spain*
Cerebellar transduction of astrocytes as gene therapy strategy for Megaloencephalic Leukoencephalopathy with subcortical cysts (MLC)

P264

Lilian Yengi *Clinical Research Development, bluebird bio, Inc.*
Evidence that prevalent SMG6 insertions are not associated with abnormal clinical findings in patients treated with Lenti-D autologous haematopoietic stem cell gene therapy for cerebral adrenoleukodystrophy

P266

Ángel Edo *Institut of Neurosciences-UAB*
Immunomodulation by gene therapy with adeno-associated vectors for the treatment of multiple sclerosis

P268

Eudald Balague *Universitat Autònoma de Barcelona-Campus Can Ruti, Badalona*
Single-intrathecal delivery of a new AAV9-mediated gene therapy vector provides long-term safe expression of frataxin and prevents neurodegeneration in a Friedreich Ataxia mouse model

P270

Maryana Bardina *Institute of Gene Biology Russian Academy of Sciences*
RNAi-based gene therapy approach for GNAO1-related neurodevelopmental disorder

P272

Enrique Garea Rodriguez *Charles River Laboratories Germany GmbH, Göttingen, Germany*
MRI-guided injections in the brain: A method for gene therapy delivery for NHP and humans

P274

Charlotte Jacobsen *Aalborg University*
Transport of therapeutic proteins across the blood-brain barrier using viral gene therapy

P276

David Rufino-Ramos *Center for Neurosciences and Cell Biology*
Extracellular vesicles for therapy of spinocerebellar ataxia type 3

P278

Annita Montepeloso *Harvard Medical School, Boston, MA*
Understanding and challenging the contribution of HSCs to brain myeloid cell turnover

P280

Mariya Volobueva *Institute of Higher Nervous Activity and Neurophysiology of RAS, Moscow, Russia*
Expression of Igf2 and its binding proteins in the hippocampus during memory formation

P282

Natalia Bal *Institute of Higher Nervous Activity and Neurophysiology of RAS, Moscow, Russia*
Processing of IGF-II in rat and mouse brain

P284

Olga Chernova *Kazan Federal University, Kazan, Russia*
Morphological evaluation of local hypothermia effects after spinal cord injury

P288

Sandrina Maçãs *Univ. Autónoma Madrid*
Generation and differentiation of an optogenetic human neural stem cell for Parkinson's disease

P290

Beatriz Fernandez *Unidad de Producción y Reprogramación Celular (UPRC), Sevilla, Spain*
Isolation of germinal matrix neural stem cells from the cerebrospinal fluid of preterm infants with intraventricular hemorrhage

Eye and ear gene therapy

P296

Steven Lee *University of Ulsan, College of Medicine*
A mTOR-inhibiting shRNA delivered intravitreally via rAAV tested as a potential anti-angiogenic gene therapeutic in a rat model of oxygen-induced retinopathy

P298

Knut Stieger *Justus-Liebig-University Giessen*
DNA sequence alterations at an I-SceI target site in murine photoreceptors following AAV mediated gene transfer

P300

Elise Boulanger-Scemama *Fondation Adolphe de Rothschild, Paris, France*
Optogenetics in the clinic: PIONEER, a phase 1/2a, open-label, non-tandomized, dose-escalation study to evaluate safety and tolerability of GS030 in subjects with retinitis pigmentosa

P302

Marina Pavlou *Ludwig-Maximilians-Universitat München*
Next-generation AAV variants for retinal gene therapy

P304

Alex Garanto *Radboud University Medical Center*
The shorter the better? Assessing novel therapeutic strategies for CRB1-associated retinal disease

P306

Stylianos Michalakis *Ludwig-Maximilians-Universität München, Munich, Germany*
Development of a gene supplementation therapy for PDE6A-linked retinitis pigmentosa

P308

Walter Habeler *I-STEM*
Set up of a tissue-engineered product consisting of RPE derived from human embryonic stem cells cultured on human amniotic membranes for the treatment of retinal diseases

P310

Axel Rossi *Hannover Medical School, Hannover, Germany*
Engineered AAV vector for improved recovery of hearing loss

P312

Wade Chien *National Institutes of Health*
AAV2.7m8 is a powerful viral vector for inner ear gene therapy

P314

Cardillia SIMON *Institut de la Vision*
Gene therapy to increase and maintain light sensitivity in cones during retinal degeneration

P316

Efrain Guzman *Oxford BioMedica*
OXB-203, a lentiviral vector expressing aflibercept as a single dose, long-term treatment for wet age-related macular degeneration

P318

Thais Bascuas Castillo *University Hospitals of Geneva*
Non-virally transfected primary human pigment epithelium cells overexpressing the oxidative stress reduction factors PEDF and GM-CSF to treat retinal neurodegeneration

P320

Salih Sanlioglu *Akdeniz University Center for Gene and Cell Therapy*
New gene therapy modalities targeting oxidative stress and microglial activation are needed for effective treatment of retinitis pigmentosa

First in man

P326

Isabelle Philipp *Siemens Healthcare Laboratory, LLC*
Development of a universal extraction protocol for multiple AAV-based gene therapy shedding assays

Immune responses to gene therapy

P330

Jean Davoust *Institut Necker Enfants-Malades; INSERM, U1151; CNRS UMR 8253*
Concurrent muscle and liver transduction imposes immune tolerance for muscle rAAV gene transfer

P332

Raisa Jofra Hernandez *SR-TIGET, Milan*
GLP-compliant long-term evaluation of toxicity and tumorigenicity following haematopoietic stem cell gene therapy in a mouse model of chronic granulomatous disease

P334

Raymond Steptoe *The University of Queensland*
Antigen-encoding bone marrow deletes mature antigen-specific B cells in recipients and inhibits antigen-specific antibody production

P336

Anna Majowicz *uniQure biopharma B.V.*
Prevalence and affinity/avidity assessment of pre-existing NABs against AAV2, 5 and 8 analyzed in the serum of 300 healthy donors

P338

Petr Ilyinskii *Selecta Biosciences*
Tolerogenic ImmTOR™ nanoparticles enhance vector transduction, mRNA synthesis and transgene expression after initial and repeated administrations of AAV-based gene therapy vectors

P340

Kirsten Bucher *Center for Ophthalmic Research Tübingen*
Potential innate immune responses to adeno-associated virus mediated gene therapy

P342

Alessandra Lopes *Université catholique de Louvain*
The antitumor activity of a DNA vaccine encoding glioma-associated antigens is enhanced by surgical resection in a GL261 glioblastoma orthotopic model

P344

Ilaria Castiglioni *San Raffaele Scientific Institute*
Metabolic insight into Cyclosporine-mediated improvement of HSPC engraftment in the context of *ex vivo* gene therapies

P346

Konstantin Ivanov *Kazan Federal University, Kazan, Russia*
Design of dna vaccine for prevention of hemorrhagic fever with renal syndrome

P348

Seyed Younes Hosseini *Shiraz University of Medical Sciences*
The inflammatory state of Hepatic stellate cells following infection by coagulation factors-shielded Adenovirus

P350

Linda Ramdani *UMR 8203, CNRS, Univ. Paris-Sud, Gustave Roussy, Université Paris-Saclay*
Epitope display on adenovirus capsid as a potent vaccination strategy to elicit cytotoxic cellular responses

P352

Sergei Abramov *Kazan Federal University, Institute of Fundamental Medicine and Biology*
Analysis of autophagy and LC3-associated phagocytosis in T-lymphocytes of patients with severe asthma

iPSC & organoids, research and therapy developments

P354

Daniel Bachiller *IMEDEA/CSIC*
A redundant control approach based on a bicistronic suicide gene construct enhances the safety and efficacy of the system

P356

Anna Rafiei *Hannover Medical School, Hannover, Germany*
Scalable GMP-compliant cultivation and haematopoietic differentiation of human iPSC enables the production of macrophages for immunotherapies

Poster session II: Thursday 24 October

P358

Vasco Meneghini *SR-TIGET, Milan*
Genome-wide analyses of regulatory regions and transcripts in hiPSC-derived neural stem/progenitor cells to define their safety and efficacy in cell therapy approaches for neurological disorders

P360

Giulia Carola *University of Barcelona*
Modeling Parkinson's disease using human midbrain-specific organoids

P362

Irene Fernández Carasa *University of Barcelona*
Mitochondrial dysfunction in iPSC-derived Parkinson's disease astrocytes

P364

Phil Sanders *University of Barcelona*
Identification of *in vitro* differentiated striatal progenitor cell sub-types for cell therapy treatment of Huntington's disease

P366

Meritxell Pons Espinal *University of Barcelona*
Using an iPS cell-based model to study neuroinflammation in Parkinson's disease

P368

Hannes Forkel *University Medicine Greifswald*
Comparison of mobilized peripheral blood with cord blood CD34+ haematopoietic stem cells as source for artificial thymic organoid derived natural killer cells

P370

Judith Estengre Pérez *CBMSO, CSIC-UAM*
Elongated human 3D neural tissue for developmental and regenerative studies: NEUROTUBES

P372

Myriam Lemmens *Novartis Pharma AG*
Prediction of sgRNA specificity for CRISPR/Cas9 genome editing by measuring DNA damage response in induced pluripotent stem cells

P374

Kirill Sukhinich *Russian Academy of Sciences, Moscow*
Therapeutic effects and homing of mesenchymal stem cell and neural progenitor cells after intra-arterial transplantation into rats with experimental ischemic stroke

P376

Inci Cevher *Hacettepe University, Ankara, Turkey*
Modeling haematopoietic niche in osteopetrosis using patient-derived induced pluripotent stem cells

P378

Alysha Burrows *Manchester Metropolitan University*
Investigating neural differentiation capacity in Alzheimer's disease iPSC-derived neural stem cells

P380

Jozef Dulak *Jagiellonian University*
Human induced pluripotent stem cells-derived cardiomyocytes efficiently engraft and improve murine heart function after myocardial infarction

P382

Elisabeth Mangiameli *SR-TIGET, Milan*
A human iPSC-based model of globoid cell leukodystrophy uncovers mutation- and cell-type specific neurodevelopmental defects

P384

Jean-Baptiste Dupont *I-STEM*
Improvement of pluripotent stem cell-derived skeletal muscle myotube maturation through the combination of physical and chemical factors

P386

Laura Batlle *CRG*
Development of CRISPR/Cas9 gene editing double-KI and brain organoid differentiation system for the study of brain development and disease

P388

Irina Ogneva *Cell Biophysics Laboratory, SSC RF – IBMP RAS, Moscow, Russia*
Cytoskeleton proteins and its epigenetic regulation in the endometriotic lesions

P390

Ute Modlich *Paul-Ehrlich-Institut*
Platelet production from murine induced pluripotent stem cells by the inducible overexpression of supporting factors

P392

Berta De la Cerda *Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER)*
Retinitis pigmentosa disease model from iPSC of a patient with PRPF31 c.165G > A mutation

P394

Yafeng Iv *Peking Union Medical College*
Production and characterization of two human induced pluripotent stem cell lines from patient with Krabbe disease

P396

Nicolas Serratrice *Hôpital La Timone (AP-HM)*
Neuroprotective effects of adipose-derived stromal vascular fraction stem cells on acute traumatic spine cord injuries in rats

P398

Ahter Dilsad Sanlioglu *Akdeniz University Center for Gene and Cell Therapy*
Resistance in human foreskin fibroblasts against lipofectamine-aided transfection of CoMiP plasmids

P400

Paula Alves *iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras*
Decoding human cardiac progenitor cells regenerative potential using advanced proteomic tools

Poster session II: Thursday 24 October

P402

Katja Puttonen *Kuopio Center for Gene and Cell Therapy, Kuopio, Finland*
Large scale manufacturing of regulatory macrophages (Mreg) in wave-type of bioreactor for clinical use

Latest news from cardiovascular and pulmonary gene therapy

P408

Ariane Biquand *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
From heart impairment characterization to pathway investigation in a Titinopathy model

P410

Luke Stuart *University of Manchester*
Development of constructs for cardiac conduction system targeted gene therapy

P412

Martin Wolf *Paracelsus Medical University, Salzburg*
Proteomic analysis reveals angiogenic and immunomodulatory function for placental stromal cell-derived extracellular vesicles

Liver gene and cell therapy

P416

Antonia Follenzi *Università del Piemonte Orientale*
Modulation of F8 promoter activity in response to Ets-1 and Ets-2 transcription factors for hemophilia A gene therapy application

P418

Daniela Cesana *SR-TIGET, Milan*
Liquid-Biopsy-Integration-Site-Sequencing (LiBIS-Seq) allows the detection of genetically modified cells residing in solid tissues and the earlier detection of premalignant clones triggered by insertional mutagenesis

P420

Andrea Annoni *SR-TIGET, Milan*
LV.InsulinB9-23/anti-CD3 inhibits recurrence of autoimmunity in NOD mice after allogeneic pancreatic islets transplant allowing T1D resolution

P424

Laia Tolosa *Experimental Hepatology Unit, Health Research Institute La Fe (IIS La Fe)*
Improved *in vivo* efficacy of clinical-grade cryopreserved human hepatocytes in mice with acute liver failure

P426

Diana Cepeda *Adverum Biotechnologies Inc., Menlo Park, California*
Biodistribution and pharmacokinetics of AAVrh.10-A1AT mediated gene therapy in humanized liver mice as a predictor of A1AT human expression levels following intravenous delivery

P428

Virginia Nieto Romero *CIEMAT/CIBERER, Madrid*
Specific gene correction of the AGXT gene and direct cell reprogramming for the treatment of Primary Hyperoxaluria Type 1

P430

Nahid Davoodian *Hormozgan University of Medical Sciences, Bandar Abbas*
HNF4a promotes haepatic differentiation of human adipose tissue-derived stem cells

P432

Eunju Lee *Korea University College of Medicine, Seoul*
CD160 serves as a negative regulator of NKT cells in acute hepatic injury

P434

Rafael Campos-Cuerva *Andalusian Network for Design and Translation of Advanced Therapies (AND&TAT)*
Haemostatic efficacy of cryopreserved nanostructured fibrin agarose hydrogel

P436

Rachel Eclov *BridgeBio*
Durable CYP21A2 gene therapy in non-human primates for treatment of congenital adrenal hyperplasia

Metabolic diseases

P440

Valeria Calbi *SR-TIGET, Milan*
Lentiviral haematopoietic stem cell gene therapy (HSC-GT) for metachromatic leukodystrophy (MLD): Preliminary results from a clinical trial with a cryopreserved formulation of OTL-200

P442

Ferran Vila Julià *Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona*
AAV-mediated gene therapy shows efficacy on the biochemical and neurological phenotype of the nucleoside-enhanced mouse model of MNGIE

P444

Andrea Calabria *SR-TIGET, Milan*
Characterization of haematopoietic system reconstitution *in vivo* in metachromatic leukodystrophy gene therapy patients

P446

Jenny Greig *University of Pennsylvania*
Liver-targeted, lipid nanoparticle encapsulated mRNA therapy corrects serum total bilirubin levels in a mouse model of Crigler-Najjar syndrome

P448

Randy Chandler *National Institutes of Health*
Adeno-associated viral gene therapy for propionic acidemia (PA)

P450

Anna Mateu Bosch *Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)*
GCDH gene therapy ameliorates glutaric aciduria type I phenotype in mice

Poster session II: Thursday 24 October

P452

Elina Makino *Sigilon Therapeutics*
Correction of Gb3 levels in alpha-Galactosidase A deficient mice by enzyme produced *in vivo* by shielded engineered cells

P454

Oihana Murillo *Center for Applied Medical Research*
Therapeutic efficacy of VTX-801 Wilson's disease mice in mice with at an advanced stage the disease

P456

Alba Tristán *Hospital Sant Joan de Déu, Barcelona*
Modelling tyrosine hydroxylase deficiency using induced pluripotent stem cells

P458

Karen Buckland *UCL Great Ormond Street Institute of Child Health*
Manufacture of an ATMP for *ex vivo* gene therapy of mucopolysaccharidosis IIIA (MPSIIIA)

P460

Juan Elías González Correa *GENyO*
Gene-cell therapy for Pompe disease

P462

Sabrina Gea-Sorlí *Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)*
Phenotype rescue by GCDH targeted gene edition in a cellular model of Glutaric Aciduria type I

P464

Ferran Vila Julià *Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona*
Codon optimization of the TYMP sequence for the gene therapy of MNGIE

P466

Alisa Shaimardanova *Kazan Federal University*
Generation and functional analysis of plasmid DNA encoding β-hexosaminidase gene for Tay-Sachs disease therapy

P468

Myoungjee Choi *Chungnam National University*
Liver–directed Pdx1 expression using recombinant AAV-2 and AAV-DJ/8 vectors in diabetic mouse model

P470

Konstantin Ivanov *Kazan Federal University, Kazan*
Reaction of liver cells to streptozocin-nicotinamide-induced diabetes mellitus in mice

P472

Xavier Sánchez *CBATEG - UAB*
Biochemical, histological and behavioural characterization of a new mouse model of Niemann-Pick C2 disease

P474

Joan Bertolin *Center for Animal Biotechnology and Gene Therapy*
Generation of a rat model of Mucopolysaccharidosis type IVA (Morquio A disease) that reproduces the human pathology

Skeletal, muscle & bone gene and cell therapy

P478

Raquel Cabrera Pérez *Blood and Tissue Bank*
Do mesenchymal stromal cells require genetic engineering to enhance their osteogenic commitment?

P480

Brahim Belbellaa *Adverum Biotechnologies Inc., Menlo Park, California*
Feasibility of gene therapy for Friedreich Ataxia-associated cardiomyopathy in non-human primates: Evaluation of delivery route, biodistribution and expression following AAVRh.10.FXN administration

P482

Sergio Antonio Munoz *CBATEG-UAB*
A new rat model of Pompe disease generated by CRISPR/Cas9 technology mimics the human disease phenotype

P484

Astrid Brull *Sorbonne Université, Inserm UMRS 974, Institut de Myologie*
Wild-type lamin A overexpression combined with mutant Lmna knock-down extends lifespan in a murine model of LMNA-congenital muscular dystrophy.

P486

Capucine Trollet *INSERM U974 Sorbonne Université Institut de Myologie*
Transduction efficiency of AAV serotypes after local injection in mouse and human skeletal muscle

P488

Eric Ehrke-Schulz *Witten/Herdecke University, Witten, Germany*
CRISPR/Cas9 mediated gene editing of Duchenne muscular dystrophy with a single gene deleted adenoviral vector

P490

Zoya Tsokolaeva *V.A.Negovsky Research Institute of General Reanimatology*
Transplantation of scf-expressing mesenchymal cell sheet activates epicardium and attenuates adverse cardiac remodeling in acute myocardial infarction

P492

Artur Fedianin *Kazan Federal University, Kazan*
Investigation of the mechanisms of reorganization of motor control in the period of postgravitational readaptation

Poster session II: Thursday 24 October

P494

Cynthia Daoud *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
A new rat model for Duchenne muscular dystrophy generated by CRISPR-induced deletion of Exon 45

P496

Zhipeng Fan *Capital Medical University School of Stomatology*
The CB1 enhanced the osteogenic differentiation ability of mesenchymal stem cells in the inflammatory environment

P498

Sang Han *Federal University of Sao Paulo*
IL-4 gene overexpression promotes repair of the ischemic skeletal muscle

P500

Margarita Codinach *Banc de Sang i Teixits*
Impact of nucleated cell isolation method on the manufacturing of mesenchymal stromal cell-based medicinal product

P502

Sandra Fuertes *Biodonostia Institute*
Structural analysis of neuromuscular junctions in aging: Effect of Sox2 heterozygosity

P504

Ilnur Ishmukhametov *Kazan Federal University*
Influence of species-specific plasmid pBUDK-ecVEGF164-ecBMP2 on osteogenesis MSC horse *in vitro*

P506

Denis Buev *Ryazan State Medical University named after academician I.P. Pavlov*
Quantitative index of cell fusion for cell therapy development

P508

Alexander van den Boom *Witten/Herdecke University, Witten*
Cell based screening of different adenoviral serotypes to identify candidates for the development of improved vectors for the treatment of muscular disorders

P510

Ilnur Ishmukhametov *Kazan Federal University*
Chitosan/gelatine/agarose nanostructured scaffolds promote angiogenesis

P512

Maxim Baltin *Kazan Federal University*
Introduction of mesenchymal stem cells reduced the effect of ischemia on nitric oxide content in the hippocampus and restored the approximate motor activity of rats after modeling of cerebral stroke

P514

Elvira Akhmetzyanova *Kazan Federal University*
Novel rat model of hindlimb ischemia for assessment of the efficiency of gene and cell therapy

P516

Luis López Navas *Andalusian Network for Design and Translation of Advanced Therapies*
Functional characterization of a proprietary GMP human platelet lysate

P518

Elvira Akhmetzyanova *Kazan Federal University*
Vegf and fgf2 genes stabilizes angiogenic effect in hind limb ischemia model in rats

P520

Artur Fedianin *Kazan Federal University*
Influence of unilateral deforming arthrosis on the condition of contralateral limb

P524

Margarita Codinach *Banc de Sang i Teixits*
New uses for existing technologies: Automated enumeration of mesenchymal stem cells with haematology analysers.

P526

Yu Cao *Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction*
Effect of secreted frizzled-related protein2 on regeneration of dental pulp stem cells

Skin gene and cell therapy

P530

Oliver March *Paracelsus Medical University Salzburg, Salzburg*
Highly efficient paired nickase-mediated correction of junctional epidermolysis bullosa via COL17A1 reframing

P532

Lucía Martínez-Santamaría *CIEMAT/CIBERER, Madrid*
Safety criteria and patient selection in a cell-based clinical trial for the systemic treatment of recessive dystrophic epidermolysis bullosa: MesenSistem-EB

P534

Ana Cardesa Gil *Andalusian Network for design and Translation of Advanced Therapies*
Compassionate use of mesenchymal stromal cells for the treatment of graft-versus-host disease

P536

Jose Bonafont *Carlos III University (UC3M), Madrid*
Highly efficient gene-editing strategies for clinically-relevant *ex vivo* correction of recessive dystrophic epidermolysis bullosa in primary patient cells

P538

Hyung-Sik Kim *Pusan National University*
Superoxide dismutase 3-introduced stem cells and their extracellular vesicles exert improved efficacy in the murine dermatitis model

P540

Thomas Kocher *Paracelsus Medical University Salzburg, Salzburg*
A selection-free COL7A1 repair strategy based on homologous recombination

P542

Laura Yndriago *Biodonostia Institute*
Characterization of aged dermal stem cell phenotype: implications for skin homeostasis

P544

Regina Kashapova *Kazan Federal University, Engineering Institute*
Development of matrixes and devices on the basis of inert materials by the method of ion-beam treatment to prototype cells and medical targets

New approaches in gene editing

P550

Lili Wang *University of Pennsylvania*
In vivo genome editing of hAPOC3 in the liver of APOC3 transgenic mouse leads to a robust and stable reduction in serum triglyceride levels and normalization of lipid profiles

P552

Sean Burns *Intellia Therapeutics*
CRISPR/Cas9-mediated gene knockout to address primary hyperoxaluria

P554

Maria Silvia *Roman Azcona Institute for Transfusion Medicine and Gene Therapy*
A versatile reporter system to identify designer epigenome modifiers for effective multiplexed epigenome editing

P556

Giulia Maule *University of Trento - CIBIO*
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing

P558

Kunwoo Lee *GenEdit*
Efficient delivery of mRNA and CRISPR in CNS using polymer nanoparticle

P560

Juan Roberto Rodriguez Madoz *Regenerative Medicine Program, CIMA Universidad de Navarra*
In vivo CRIPSR/Cas9 Ldha inhibition as universal treatment for primary hyperoxaluria

P564

Christina Fuentes *University of California, Berkeley*
An engineered self-inactivating adeno-associated virus mediated Cas9 delivery system for therapeutic genome editing

P566

Julia Fakhiri *Heidelberg University Hospital*
Kill-switch and self-inactivating AAV vectors based on CRISPR/Cas9 for precise control of *in vivo* gene expression

P568

Estel Aparicio Prat *Simulation and Modeling Sciences, Pfizer, Cambridge*
Using CRISPR base editors to perform targeted mutagenesis screenings for mechanism of action discovery

P570

Teresa Rojo Romanos *TU Dresden*
Designer recombinase for precise excision of HTLV-1

P572

Omer Anakok *Ataturk University*
Direct transgene expression and mAb production by using new generation minimised UCOEs on human iPS and CHO cells

P574

François Moreau-Gaudry *INSERM U1035 Universite Bordeaux*
CRISPR-Cas9 genome editing induces megabase-scale deletions

P578

Francesca Tasca *Leiden University Medical Centre*
High-capacity adenoviral vectors encoding full-length dystrophin and CRISPR-Cas9 nucleases for targeted correction of myogenic cells from Duchenne muscular dystrophy patients

P580

Aida Garcia Torralba *CIEMAT/CIBERER, Madrid*
Efficient generation of knock-out mice by *in vitro* and *in vivo* electroporation of CRISPR/Cas9 system to model rare metabolic inherited diseases and cancer predisposition

P582

Álex Jiménez Félix *University of Barcelona*
Gene therapy by correction of point mutations in the endogenous locus of mammalian cells using Repair-PolyPurine Reverse Hoogsteen hairpins

P584

Cristina Rocha *AstraZeneca, Biopharmaceutical R&D*
Defining safety margins of therapeutic genome editing by understanding mechanisms and liabilities of CRISPR-based molecular entities

P586

Sabina Sánchez Hernández *GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia*
Development of cellular models to study efficiency and safety of gene repair in Wiskott-Aldrich syndrome

P588

Jeongpil Han *Seoul National University*
Cell cycle determines efficiency of homology directed repair depending on the integrity of nuclear envelope

Poster session II: Thursday 24 October

P590

Irina Starostina *Kazan Federal University*
Gene modification of HEK293A cells using CRISPR-Cas9 SAM technology for the transcriptional activation of dysferlin gene

P592

Takahiro Nakamura *Kyushu University*
Designer RNA binding protein based on PPR protein, as a new modality for targeted therapy

P594

Andrew Olsen *Aldevron*
Aldevron's CRISPR-associated nucleases for gene editing: Tools to support discovery and therapeutic programs

New delivery systems

P600

Antonia Follenzi *Universita del Piemonte Orientale*
Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A

P602

María Sancho *CIBER-BBN*
Combination of exosomes and near-infrared responsive gold nanoparticles: New selective and specific therapeutic vehicle.

P604

Gaelle Vandermeulen *University of Louvain*
DNA immunization against tumor epitopes using a versatile delivery platform that exploits inherent mechanisms of antiviral defense

P606

Francesco Piras *SR-TIGET, Milan*
Exploring combinatorial relief of multiple innate immune blocks for efficient gene engineering of quiescent human haematopoietic stem cells

P608

Pilar Puig Serra *Centro Nacional de Investigaciones Oncológicas*
Development of virus-like particles for CRISPR/Cas9 targeted delivery

P610

Ya-Fang Mei *Institute of Clinical Microbiology, Virology, Umeå University*
Transcriptome analysis of metastatic prostate cells infected by oncolytic adenovirus 11p encoded ADP gene (RCAd11pADP) expose important antitumor pathways

P612

Mahito Nakanishi *National Institute of Advanced Industrial Science and Technology (AIST)*
Development of stealth RNA vector (SRV) for innovative gene and cell therapy

P614

Eirini Vamva *University of Cambridge*
Towards optimising lentiviral vectors for gene therapy through structure informed genome modification

P616

Tomoyuki Nishikawa *Osaka University*
Development of antitumor immunity inducing RNA drug and a novel pyro-drive jet injector

P618

Ekaterina Slobodkina *Faculty of Medicine, Lomonosov Moscow State University*
Combined plasmid delivery of angiogenic growth factors: Preclinical assessment of different approaches

P620

Lorena de Oñate *UC Berkeley*
Delivery of an endosomolytic CRISPR-Cas9 RNP via receptor-mediated endocytosis for cell-targeted genome editing

P622

Chuanyu Zhuang *Hanyang University*
RAGE-targeting delivery of anti-microRNA-92a antagomir for the treatment of acute lung injury

P624

Chin Yang Chang *Osaka University*
Development of novel injector: Pyro-Drive Jet Injector (PJI) application to intradermal DNA vaccination

P626

Sirina Kurbangaleeva *Kazan Federal University*
Mesenchymal stem cells derived membrane vesicles induced by cytochalasin B demonstrate immunomodulatory properties

P628

Natalia Bal *Institute of Higher Nervous Activity and Neurophysiology of RAS, Moscow*
Effect of intranasal administration of mesenchymal stem cells on the average speed of movement and time of activity and NO level in olfactory bulb of rats after simulation of brain stroke

P630

Keita Takahashi *Gifu Pharmaceutical University*
Identification of cellular targets for DNA delivery from recombinant L. lactis strains *in vivo*

P632

Hiu Man Grisch *University Children's Hospital Zurich and Children's Research Center*
Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads

P634

Olga Neustroeva *Kazan Federal University*
Cytokine profile and immunophenotype of cytochalasin B induced membrane vesicles

P636

Geraldine Peyrou *Polyplus Transfection*
Non-viral *in vivo* mRNA delivery for cancer research, vaccination or gene therapy

P638

Junkyu Ha *Hanyang University*
A fusion peptide with an LPS-binding peptide and a RAGE-binding peptide as a carrier of plasmid DNA with anti-inflammatory effects

P640

Ilnur Ishmukhametov *Kazan Federal University*
Assessment of toxicity of planar shaped nanomaterials using flow cytometry

P642

Virginia Arechavala *Biocruces Bizkaia Health Research Institute*
A COST network to improve the delivery of antisense RNA therapeutics

P644

Myoungjee Choi *Hanyang University*
A mixed micelle of His-Arg conjugated PAMAM G2 with cholesterol and Glycyrrhizic acid as gene delivery system into the lung cells

P646

Ilnur Ishmukhametov *Kazan Federal University*
Encapsulation of E. coli bacteria cells with polyelectrolytes as a method of obtaining microcapsules for targeted drug delivery

P648

Yulia Yuzefovych *Hannover Medical School*
Generation of immunologically invisible transgenic porcine pancreatic islet cell clusters after single cell engineering and islet reassembling to support xenograft survival

P650

Ilnur Ishmukhametov *Kazan Federal University*
Hyperspectral microscopy in the characterization of aluminosilicate halloysite nanocontainers

Regulatory session

P656

Roke Iñaki Oruezabal Guijarro *Andalusian Network for Design And Traslation of Advanced Therapies*
Regulatory framework for innovation assessment in advanced therapies in Europe

P658

Myriam Lemmens *Novartis Pharma AG*
Transformation potential of CRIPSR/Cas9 based genome editing can be assessed by soft agar colony formation assay and growth in low attachment plates

P660

Álvaro Ritoré Hidalgo *Andalusian Network for Design and Translation of Advanced Therapies*
Public healthcare system as key player in leveraging advanced therapy supply chains

P662

Diane Seimetz *Biopharma Excellence*
ATMPs at the transition from nonclinical to clinical stage: How to smartly mitigate risk and uncertainties

P664

Elena Meurer *Biopharma Excellence*
Preserve and recreate: Manufacturing and quality development for tissue, gene and cell therapy products

P666

Florian Durst *Thermo Fisher Scientific*
A rapid alternative to culture based mycoplasma detection

P668

Liliya Chernova *Kazan Federal University*
Nontrivial properties of small heat shock protein IbpA from Acholeplasma laidlawii

Other

P670

Jessika Ceiler *NCT / DKFZ, Heidelberg*
Role of Mitochondria-Associated Membranes in recombinant AAV mitochondrial integration and trafficking

P672

Mercedes Lopez-Santalla *CIEMAT/CIBERER, Madrid*
Long-term protective effects of adipose-derived mesenchymal stromal cell therapy in experimental colitis

P674

Fabiola Lora Ulgar *Andalusian Network for Design and Translation of Advanced Therapies*
Safety, feasibility and trends of efficacy of intravenous injection of autologous adipose-derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: A phase I-IIa multicenter randomized triple blind placebo controlled trial

P676

Rocio Sampayo *University of California, Berkeley*
Mechanical tuning of adult hippocampal neural stem cells using light-responsive Rho GTPases dictates cell fate

P678

Adriano de Marino *SR-TIGET, Milan*
ISwap: a bioinformatics tool for index switching detection in vector integration site studies

P680

Sandra Laner-Plambeger *Department for Transfusion Medicine, Paracelsus Medical University Salzburg*
Upregulation of mitotic bookmarking transcription factors may induce enhanced proliferation of human stromal cells by human platelet lysate

P682

Anastasia Efimenko *Lomonosov Moscow State University*
Tissue-specific interaction of stromal cells and endothelium *in vitro* leads to a distinct pattern of angiogenic response

Poster session II: Thursday 24 October

P684

Nuria Nieto-Nicolau *Barcelona Tissue Bank & donor center*
Good manufacturing production of limbal stem cells in a tissue bank for clinical application

P686

Esther López *Centro de Cirugía de Mínima Invasión Jesús Usón*
Efficacy of intracoronary administration of microencapsulated hepatocyte growth factor in a reperfused myocardial infarction swine model

P688

Esther López *Centro de Cirugía de Mínima Invasión Jesús Usón*
Effects of early intrapericardial delivery of microvesicles obtained from heart-derived cells in cardiac function in an experimental myocardial infarction in swine.

P690

Roke Iñaki Oruezabal-Guijarro *Andalusian Network for Design And Traslation of Advanced Therapies*
External quality control program in advanced therapies

P692

Nuria Nieto-Nicolau *Barcelona Tissue Bank & donor center*
Integrin α6 improves stemness, proliferation and migration in human mesenchymal stem cells

P694

Raquel Fernández Pérez *CIEMAT/CIBERER, Madrid*
Role play by galectin-1 in regulatory CD4+ T cell therapy for modulation of immune responses in experimental colitis

P696

Seung-Bin Yoon *Korea Research Institute of Bioscience and Biotechnology (KRIBB)*
Quantitative analysis of spliced X-box binding protein 1 (XBP1) using universal primer for quantitative RT-PCR

P698

Ruth Rieser *Ludwig-Maximilians-Universitat München*
Effect of salt and sugar on the storage stability of liquid and freeze-dried adeno-associated virus formulations

P700

Lucia Dunajova *Synthace Ltd, London*
Antha – a powerful software solution for the automated laboratory of the future

P702

Paul Foulds *Cell Therapy Catapult*
Leaders in cryogenic RFID technology

P704

Regina Kashapova *Kazan Federal University, Engineering Institute*
Electromyographic analysis of the injured limb